Page last updated: 2024-10-23

aspirin and Peripheral Arterial Diseases

aspirin has been researched along with Peripheral Arterial Diseases in 222 studies

Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.

Research Excerpts

ExcerptRelevanceReference
"In patients with chronic coronary artery disease (CAD) and/or peripheral artery disease (PAD) enrolled in The Cardiovascular Outcomes for People Using Anticoagulation Strategies trial, the effects of rivaroxaban 2."9.51Rivaroxaban and aspirin vs. aspirin alone in Asian compared with non-Asian patients with chronic coronary artery disease or peripheral arterial disease: the COMPASS trial. ( Bhatt, DL; Bosch, J; Connolly, SJ; Eikelboom, JW; Fox, KAA; Hori, M; Liang, Y; Maggioni, A; Yusuf, S; Zhu, J, 2022)
"Clopidogrel is recommended in international guidelines to prevent arterial thrombotic events in patients with peripheral arterial disease (PAD)."9.51CYP2C19 genotype-guided antithrombotic treatment versus conventional clopidogrel therapy in peripheral arterial disease: study design of a randomized controlled trial (GENPAD). ( Adang, E; Coenen, M; Deneer, V; Donders, R; Kramers, C; Kranendonk, J; Reijnen, M; Vijver-Coppen, RV; Warlé, MC; Willems, LH; Zeebregts, CJ, 2022)
"5 mg twice daily rivaroxaban and aspirin in patients with polyvascular disease (coronary artery disease, peripheral arterial disease or both), the underlying mechanism of which is not clearly understood."9.34Synergistic influence of rivaroxaban on inflammation and coagulation biomarkers in patients with coronary artery disease and peripheral artery disease on aspirin therapy. ( Bafford, R; Cummings, C; Gonze, M; Gurbel, P; Mackrell, P; Rout, A; Sukhi, A; Tantry, U; Ulloa, K, 2020)
"5 mg twice daily and aspirin 100 mg once daily compared with aspirin 100 mg once daily reduced major adverse cardiovascular events and mortality and increased bleeding."9.30Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin. ( Berkowitz, SD; Bhatt, DL; Bosch, JJ; Cairns, JA; Connolly, SJ; Cook Bruns, N; Dagenais, GR; Diaz, R; Eikelboom, JW; Fox, KAA; Hart, RG; Leong, DP; Maggioni, AP; Muehlhofer, E; O'Donnell, M; Shestakovska, O; Tasto, C; Yusuf, S, 2019)
"In patients with chronic coronary artery disease or peripheral artery disease and a history of mild or moderate HF, combination rivaroxaban and aspirin compared with aspirin alone produces similar relative but larger absolute benefits than in those without HF."9.30Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease. ( Avezum, A; Bhatt, DL; Bosch, J; Branch, KR; Cheng, RK; Connolly, SJ; Eikelboom, JW; Fox, KAA; Maggioni, AP; Probstfield, JL; Shestakovska, O; Yusuf, S, 2019)
"PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis In Myocardial Infarction 54) randomized 21,162 patients with prior MI (1 to 3 years) to ticagrelor 90 mg twice daily, ticagrelor 60 mg twice daily, or placebo, all on a background of low-dose aspirin."9.22Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. ( Abola, MTB; Aylward, P; Bhatt, DL; Bonaca, MP; Braunwald, E; Cohen, M; Corbalán, R; Dalby, A; Dellborg, M; Goodrich, E; Held, P; Jensen, EC; Kuder, J; López-Sendón, J; Nicolau, JC; Parkhomenko, A; Sabatine, MS; Špinar, J; Steg, PG; Storey, RF, 2016)
"This study aims to evaluate whether cilostazol plus aspirin is more efficacious than aspirin alone for preventing progression of atherosclerosis in patients with ischemic stroke or transient ischemic attack (TIA) who also have peripheral arterial disease."9.20The efficacy and safety of cilostazol in ischemic stroke patients with peripheral arterial disease (SPAD): protocol of a randomized, double-blind, placebo-controlled multicenter trial. ( Chen, CH; Chen, ST; Chern, CM; Chiou, HY; Chiu, HC; Hsu, CY; Hu, HH; Jeng, JS; Lee, JT; Lien, LM; Lin, HJ; Lin, RT; Liu, CH; Ma, H; Po, HL; Sun, MC; Sun, MH; Sun, Y, 2015)
"Patients with PAD on ASA therapy at baseline were included from the ongoing Effect of Lipid Modification on Peripheral Arterial Disease after Endovascular Intervention Trial (ELIMIT), which is a randomized trial testing whether combination treatment with ezetimibe, niacin, and a statin will halt/regress atherosclerosis compared with statin monotherapy."9.15Variability and persistence of aspirin response in lower extremity peripheral arterial disease patients. ( Ballantyne, CM; Dong, JF; Kimball, KT; Lumsden, AB; Morrisett, JD; Nambi, V; Saunders, J; Virani, SS, 2011)
" aspirin and placebo on platelet aggregation in peripheral arterial disease (PAD) patients."9.14Thromboxane Antagonism with terutroban in Peripheral Arterial Disease: the TAIPAD study. ( Bounameaux, H; Cairols, MA; Clement, DL; Coccheri, S; Fiessinger, JN; Fletcher, JP; Hoffmann, U; Turpie, AG, 2010)
"Vorapaxar is a novel antiplatelet agent that has demonstrated efficacy in reducing atherosclerotic events in patients with a history of MI or PAD without a history of stroke, transient ischemic attack, or ICH when taken in combination with aspirin and clopidogrel."8.91Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease. ( Arif, SA; D'Souza, J; Gil, M; Gim, S, 2015)
" The currently available antiplatelet drugs used to prevent vascular events in patients with cardiovascular disease, including peripheral arterial disease (PAD), include aspirin and thienopyridines such as clopidogrel."8.86[The basis of platelets: platelets and atherothrombosis: an understanding of the lack of efficacy of aspirin in peripheral arterial disease (PAD) and diabetic patients]. ( Bal dit Sollier, C; Drouet, L; Henry, P, 2010)
"Dual pathway inhibition (DPI) with low-dose rivaroxaban and aspirin in patients with coronary artery disease (CAD) and/or peripheral artery disease (PAD) reduces the occurrence of cardiovascular (CV) events; however, the underlying mechanisms explaining these latter CV benefits are not clearly understood."8.31Dual Pathway Inhibition with Rivaroxaban and Aspirin Reduces Inflammatory Biomarkers in Atherosclerosis. ( Attena, E; Cotticelli, C; D'Alterio, G; D'Onofrio, A; Fabiani, D; Golino, P; Leonardi, S; Maione, B; Nigro, G; Rago, A; Russo, V; Sarpa, S, 2023)
" This study aims to compare the impact of aspirin (ASA) monotherapy, P2Y12 monotherapy, and DAPT on limb salvage (LS), amputation-free survival (AFS), and overall survival (OS) in patients undergoing lower extremity peripheral endovascular intervention (PVI) for chronic limb-threatening ischemia (CLTI)."8.12P2Y12 inhibitor monotherapy is associated with superior outcomes as compared with aspirin monotherapy in chronic limb-threatening ischemia. ( Dosluoglu, HH; Dryjski, ML; Fakhoury, E; Harris, LM; Khan, SZ; Montross, B; O'Brien-Irr, MS; Rivero, M, 2022)
" The COMPASS trial has shown that in patients with stable coronary artery disease (CAD) or peripheral artery disease (PAD), low-dose rivaroxaban (2."8.12[ANMCO Position paper: Evidence and practical indications for the use of low-dose rivaroxaban in stable coronary artery disease and peripheral artery disease]. ( Altamura, V; Bianco, M; Caldarola, P; Ceravolo, R; Cipriani, M; Colivicchi, F; De Luca, L; Di Fusco, SA; Francese, GM; Gabrielli, D; Gulizia, MM; Lucà, F; Nardi, F; Navazio, A; Oliva, F; Riccio, C; Rizzello, V; Scicchitano, P; Valente, S, 2022)
"This study aimed to investigate the cost-effectiveness of low-dose rivaroxaban plus aspirin versus aspirin alone for patients with stable cardiovascular diseases in the Taiwan setting."8.02Cost-effectiveness analysis of rivaroxaban plus aspirin versus aspirin alone in secondary prevention among patients with chronic cardiovascular diseases. ( Chang, WT; Chen, ZC; Chou, CC; Lee, MC; Liao, CT; Strong, C; Toh, HS; Wu, WS; Yu, T, 2021)
"The goal of this study is to establish the prevalence of high on-treatment platelet reactivity to aspirin (HPRA) and clopidogrel (HPRC) in patients with critical limb ischemia (CLI)."7.88Prevalence of high on-treatment (aspirin and clopidogrel) platelet reactivity in patients with critical limb ischemia. ( Al-Asady, N; Caro, J; Clavijo, LC; Dhillon, A; Matthews, RV; Rowe, V; Shavelle, DM; Tun, H, 2018)
"Our aims were to examine the prevalence and genetic predictors of aspirin and clopidogrel high on-treatment platelet reactivity (HoTPR), and associated adverse cardiovascular outcomes in patients with peripheral arterial disease (PAD)."7.88Aspirin and clopidogrel high on-treatment platelet reactivity and genetic predictors in peripheral arterial disease. ( Amsterdam, EA; Anderson, D; Armstrong, EJ; Chen, DC; Chiamvimonvat, N; Hua, A; Laird, JR; Li, CS; López, JE; Singapuri, A; Westin, GG; Yeo, KK, 2018)
"To evaluate long-term health benefits and risks of adding vorapaxar (VOR) to the standard care antiplatelet therapy (SC) of aspirin and/or clopidogrel, among a population with a recent myocardial infarction (MI) and/or peripheral artery disease (PAD)."7.85State transition model: vorapaxar added to standard antiplatelet therapy to prevent thrombosis post myocardial infarction or peripheral artery disease. ( Chase, M; Davies, G; Du, M; Oguz, M, 2017)
"Clopidogrel or aspirin are indicated for patients with recent ischemic stroke (IS) or established peripheral artery disease (PAD)."7.81Clopidogrel versus aspirin in patients with recent ischemic stroke and established peripheral artery disease: an economic evaluation in a Chinese setting. ( Ben, H; Li, T; Liu, M; Wu, B; Xu, Z; Zhong, H, 2015)
"Clopidogrel, cilostazol, and aspirin were compared in terms of efficacy and safety for primary prevention of stroke in peripheral artery disease (PAD) patients."7.79Cilostazol for primary prevention of stroke in peripheral artery disease: a population-based longitudinal study in Taiwan. ( Chu, CY; Hsu, PC; Lai, WT; Lee, WH; Lin, TH; Sheu, SH; Su, HM; Voon, WC, 2013)
"The novel P2Y12 antagonist ticagrelor inhibits adenosine diphosphate (ADP)-induced platelet aggregation more potently than clopidogrel and reduces the incidence of myocardial infarction and total death in patients with an acute coronary syndrome (ACS)."7.79Ticagrelor improves peripheral arterial function in patients with a previous acute coronary syndrome. ( Erlinge, D; Larsson, J; Ohman, J; Salmi, H; Torngren, K, 2013)
"Patients with peripheral artery disease (PAD) following peripheral percutaneous transluminal angioplasty (PTA) with stent implantation are prone to stent thrombosis despite treatment with aspirin and clopidogrel."7.79Impaired responsiveness to clopidogrel and aspirin in patients with recurrent stent thrombosis following percutaneous intervention for peripheral artery disease. ( Frołow, M; Mazur, P; Niżankowski, R; Sadowski, J; Undas, A, 2013)
"Patients with lower extremity peripheral artery disease (PAD) are at increased risk of major adverse limb events (MALE)."6.72The efficacy and safety of direct oral anticoagulants plus aspirin in symptomatic lower extremity peripheral arterial disease: a systematic review and meta-analysis of randomized controlled trials. ( Costa, G; Gonçalves, L; Teixeira, R, 2021)
"However, both trials revealed excess diplopia (double vision) usually reversible after vorapaxar."6.53Vorapaxar and diplopia: Possible off-target PAR-receptor mismodulation. ( Can, M; Fortmann, SD; Hanley, DF; Kim, MH; Lordkipanidze, M; Marciniak, TA; Rao, SV; Serebruany, VL; Tanguay, JF, 2016)
"5 mg twice daily to aspirin or dual antiplatelet therapy significantly reduced this risk, with an increase in the bleeding risk, but had a favorable benefit risk for patients treated with bypass surgery, regardless of conduit type."5.69Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits. ( Anand, SS; Bauersachs, RM; Berkowitz, SD; Bonaca, MP; Capell, WH; Chung, J; Conte, MS; Debus, S; Dorigo, W; Govsyeyev, N; Gudz, I; Haskell, LP; Hess, CN; Jaeger, N; Krievins, D; Mills, J; Moll, F; Muehlhofer, E; Nehler, M; Norgren, L; Patel, MR; Piffaretti, G; Powell, R; Sillesen, H; Szalay, D; Szarek, M; Wohlauer, M, 2023)
"COMPASS trial patients with IAD <15 mmHg and IAD >15 mmHg were compared with respect to thirty-month incidence risk of: 1) composite of stroke, myocardial infarction, or cardiovascular death (MACE), 2) composite of acute limb-ischemia or vascular amputation (MALE), 3) composite of MACE or MALE, and 4) effects of treatment with the combination versus aspirin alone on these outcomes."5.69The predictive value of interarm systolic blood pressure differences in patients with vascular disease: Sub-analysis of the COMPASS trial. ( Aboyans, V; Anand, S; Bosch, J; Connolly, S; Eikelboom, J; Muehlhofer, E; Qadura, M; Syed, MH; Yusuf, S, 2023)
"5 mg twice daily plus aspirin, and to report their clinical outcomes and bleeding rates in clinical practice compared to the COMPASS randomized trial, which provided the basis for using DPI in this patient population."5.51Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: The XATOA Registry. ( Aboyans, V; Anand, SS; Bosch, J; Cowie, MR; Debus, ES; Fox, KAA; Gay, A; Patel, M; Vogtländer, K; Welsh, RC; Zeymer, U, 2022)
"In patients with chronic coronary artery disease (CAD) and/or peripheral artery disease (PAD) enrolled in The Cardiovascular Outcomes for People Using Anticoagulation Strategies trial, the effects of rivaroxaban 2."5.51Rivaroxaban and aspirin vs. aspirin alone in Asian compared with non-Asian patients with chronic coronary artery disease or peripheral arterial disease: the COMPASS trial. ( Bhatt, DL; Bosch, J; Connolly, SJ; Eikelboom, JW; Fox, KAA; Hori, M; Liang, Y; Maggioni, A; Yusuf, S; Zhu, J, 2022)
"Clopidogrel is recommended in international guidelines to prevent arterial thrombotic events in patients with peripheral arterial disease (PAD)."5.51CYP2C19 genotype-guided antithrombotic treatment versus conventional clopidogrel therapy in peripheral arterial disease: study design of a randomized controlled trial (GENPAD). ( Adang, E; Coenen, M; Deneer, V; Donders, R; Kramers, C; Kranendonk, J; Reijnen, M; Vijver-Coppen, RV; Warlé, MC; Willems, LH; Zeebregts, CJ, 2022)
"The Clopidogrel and Acetylsalicylic Acid in Bypass Surgery for Peripheral Arterial Disease (CASPAR) trial is the only large, double-blind, placebo-controlled trial of dual antiplatelet therapy (DAPT) versus aspirin in patients with peripheral artery disease (PAD) after lower extremity revascularization (LER)."5.51Efficacy and safety of rivaroxaban versus placebo after lower extremity bypass surgery: A post hoc analysis of a "CASPAR like" outcome from VOYAGER PAD. ( Anand, SS; Bauersachs, RM; Berkowitz, SD; Bonaca, MP; Debus, ES; Haskell, LP; Muehlhofer, E; Nehler, MR; Patel, MR; Szarek, M, 2022)
"Most parameters of thrombus formation under flow were similarly high for the patient and control groups."5.42Normal platelet activation profile in patients with peripheral arterial disease on aspirin. ( Baaten, CC; Clemetson, KJ; Cosemans, JM; de Laat, B; Heemskerk, JW; Kleinegris, MC; Roest, M; Ten Cate, H; van Geffen, JP; Verdoold, R, 2015)
" Furthermore, the current evidence seems to support that single-drug antiplatelet can be used as the basic treatment, and new antithrombotic strategies, such as ticagrelor only or aspirin combined with low-dose rivaroxaban are expected to further reduce the incidence of stroke for ICVD patients with PAD."5.41Early identification and treatment for peripheral arterial disease in patients with ischemic cerebrovascular disease. ( Li, LG; Ma, X, 2023)
"5 mg twice daily and aspirin 100 mg once daily compared with aspirin 100 mg once daily reduced major adverse cardiovascular events (MACE) in patients with chronic coronary artery disease or peripheral artery disease by 24% during a mean follow-up of 23 months."5.41Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease. ( Anand, SS; Berkowitz, SD; Bosch, J; Connolly, SJ; Dagenais, GR; Eikelboom, JW; Fox, KA; Guzik, TJ; Keller, L; Liang, Y; Liu, L; Muehlhofer, E; O'Donnell, M; Shestakovska, O; Yusuf, S; Zhu, J, 2021)
"Incident composite of myocardial infarction, stroke or cardiovascular death was estimated per 100 person-years (py) during randomised treatment (n=18 278) and after study treatment discontinuation to non-study aspirin (n=14 068)."5.41Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease. ( Aboyans, V; Berkowitz, SD; Bhatt, DL; Bosch, JJ; Connolly, SJ; Dagenais, GR; Dyal, L; Eikelboom, JW; Fox, KAA; Leong, DP; Muehlhofer, E; Probstfield, JL; Widimsky, P; Winkelmann, BR; Yusuf, S, 2021)
"5 mg rivaroxaban twice daily and 100 mg aspirin once daily compared with 100 mg aspirin once daily reduces major adverse cardiovascular (CV) events in patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD)."5.41Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease. ( Anand, SS; Avezum, A; Berkowitz, SD; Bhatt, DL; Bosch, J; Branch, KRH; Connolly, SJ; Dagenais, GR; Eikelboom, JW; Félix, C; Fox, KAA; Guzik, TJ; Hart, RG; Maggioni, AP; Muehlhofer, E; Sharma, M; Shestakovska, O; Yusuf, S, 2021)
"Atherosclerosis is a chronic inflammatory disease of the vessel wall."5.36Aspirin-triggered lipoxin and resolvin E1 modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis. ( Conte, MS; Creager, MA; Ho, KJ; Kroemer, AH; Lancero, H; Owens, CD; Pande, R; Serhan, CN; Spite, M, 2010)
"5 mg twice daily rivaroxaban and aspirin in patients with polyvascular disease (coronary artery disease, peripheral arterial disease or both), the underlying mechanism of which is not clearly understood."5.34Synergistic influence of rivaroxaban on inflammation and coagulation biomarkers in patients with coronary artery disease and peripheral artery disease on aspirin therapy. ( Bafford, R; Cummings, C; Gonze, M; Gurbel, P; Mackrell, P; Rout, A; Sukhi, A; Tantry, U; Ulloa, K, 2020)
"5 mg twice daily plus aspirin was associated with a significantly lower incidence of the composite outcome of acute limb ischemia, major amputation for vascular causes, myocardial infarction, ischemic stroke, or death from cardiovascular causes than aspirin alone."5.34Rivaroxaban in Peripheral Artery Disease after Revascularization. ( Anand, SS; Bauersachs, RM; Berkowitz, SD; Bonaca, MP; Brodmann, M; Capell, WH; Debus, ES; Diao, L; Diaz, R; Fanelli, F; Gudz, I; Haskell, LP; Hess, CN; Hiatt, WR; Jaeger, N; Kittelson, JM; Krievins, DK; Mátyás, L; Muehlhofer, E; Nehler, MR; Pap, AF; Patel, MR, 2020)
" There were no statistically significant differences between rivaroxaban and aspirin prophylaxis for recurrent ischemic stroke in patients with non-stenotic intracranial atherosclerosis and/or systemic atherosclerosis."5.34Intracranial and systemic atherosclerosis in the NAVIGATE ESUS trial: Recurrent stroke risk and response to antithrombotic therapy. ( Amarenco, P; Ameriso, SF; Bereczki, D; Berkowitz, SD; Connolly, SJ; Ferrari, J; Firstenfeld, A; Hart, RG; Kasner, SE; Lang, W; Lavados, P; Mikulik, R; Mundl, H; Ntaios, G; Pearce, LA; Perera, KS; Povedano, GP; Uchiyama, S; Yoon, BW, 2020)
"5 mg twice daily and aspirin 100 mg once daily compared with aspirin 100 mg once daily reduced major adverse cardiovascular events and mortality and increased bleeding."5.30Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin. ( Berkowitz, SD; Bhatt, DL; Bosch, JJ; Cairns, JA; Connolly, SJ; Cook Bruns, N; Dagenais, GR; Diaz, R; Eikelboom, JW; Fox, KAA; Hart, RG; Leong, DP; Maggioni, AP; Muehlhofer, E; O'Donnell, M; Shestakovska, O; Tasto, C; Yusuf, S, 2019)
"Strokes were significantly reduced by the combination of rivaroxaban plus aspirin in comparison with aspirin in the COMPASS trial (Cardiovascular Outcomes for People Using Anticoagulation Strategies)."5.30Stroke Outcomes in the COMPASS Trial. ( Aboyans, V; Alings, M; Berkowitz, SD; Bhatt, DL; Bosch, J; Bruns, NC; Catanese, L; Connolly, SJ; Eikelboom, JW; Fox, K; Ha, JW; Hart, RG; Keltai, K; Maggioni, A; Ng, KKH; O'Donnell, M; Sharma, M; Shestakovska, O; Tonkin, A; Varigos, J; Yusuf, S, 2019)
" In patients with prior coronary artery disease or peripheral arterial disease the COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trial revealed that compared with acetylsalicylic acid alone, dual pathway inhibition with low-dose rivaroxaban (2."5.30Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease. ( Coppens, M; Eikelboom, JWA; Weitz, JI, 2019)
"5 mg bd plus aspirin), versus aspirin alone, are preserved in patients with moderate renal dysfunction without evidence of an excess hazard of bleeding."5.30Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS Trial. ( Connolly, SJ; Eikelboom, JW; Fox, KAA; Metsarinne, KP; Shestakovska, O; Yusuf, S, 2019)
"In patients with chronic coronary artery disease or peripheral artery disease and a history of mild or moderate HF, combination rivaroxaban and aspirin compared with aspirin alone produces similar relative but larger absolute benefits than in those without HF."5.30Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease. ( Avezum, A; Bhatt, DL; Bosch, J; Branch, KR; Cheng, RK; Connolly, SJ; Eikelboom, JW; Fox, KAA; Maggioni, AP; Probstfield, JL; Shestakovska, O; Yusuf, S, 2019)
" The combination of rivaroxaban plus aspirin compared with aspirin alone reduced the composite endpoint of cardiovascular death, myocardial infarction, or stroke (126 [5%] of 2492 vs 174 [7%] of 2504; hazard ratio [HR] 0·72, 95% CI 0·57-0·90, p=0·0047), and major adverse limb events including major amputation (32 [1%] vs 60 [2%]; HR 0·54 95% CI 0·35-0·82, p=0·0037)."5.27Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. ( Aboyans, V; Alings, M; Anand, SS; Avezum, AA; Bangdiwala, SI; Bhatt, DL; Bosch, J; Branch, K; Chen, E; Commerford, PJ; Connolly, SJ; Diaz, R; Eikelboom, JW; Fox, KAA; Hart, RG; Kakkar, AK; Keltai, K; Leong, DP; Lewis, BS; Lopez-Jaramillo, P; Maggioni, AP; Misselwitz, F; O'Donnell, M; Pogosova, N; Ryden, L; Störk, S; Vanassche, T; Varigos, JD; Vinereanu, D; Widimsky, P; Yusuf, S; Zhu, J, 2018)
"These results suggest that patients who have undergone EVT have similar risks for major and life-threatening bleeding events with edoxaban and aspirin compared with clopidogrel and aspirin."5.27Edoxaban Plus Aspirin vs Dual Antiplatelet Therapy in Endovascular Treatment of Patients With Peripheral Artery Disease: Results of the ePAD Trial. ( Adams, G; Ansel, G; Baumgartner, I; Grosso, M; Jaff, M; Lin, M; Mercur, MF; Minar, E; Moll, F; Nwachuku, C; Rundback, J; Tangelder, M; Zeller, T, 2018)
"The DAPT (Dual Antiplatelet Therapy) study randomized 11,648 patients free from ischemic and bleeding events 12 months after coronary stenting to continued thienopyridine plus aspirin therapy for an additional 18 months versus aspirin therapy alone."5.24Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study. ( Apruzzese, PK; Cutlip, DE; Kereiakes, DJ; Massaro, JM; Mauri, L; Secemsky, EA; Steg, PG; Yeh, RW, 2017)
"To perform a systematic literature review and indirect treatment comparison (ITC) to identify, summarize and quantify randomized controlled trial (RCT) evidence evaluating combination anticoagulant or P2Y12 inhibitor with low-dose aspirin versus low-dose aspirin alone for the prevention of atherothrombotic events in patients with stable coronary artery disease (CAD) and/or peripheral artery disease (PAD)."5.22Combination anticoagulant or P2Y12 inhibitor with low-dose aspirin versus low-dose aspirin alone in patients at risk or with documented coronary and/or peripheral artery disease. ( Baker, WL; Bookhart, B; Coleman, CI; Kharat, AA, 2022)
" Clinical equipoise also persists around questions such as the utility of dual antiplatelet therapy in conjunction with rivaroxaban after high-risk endovascular interventions and the optimal therapy for patients experiencing acute limb ischemia."5.22Antithrombotic Therapy in Peripheral Artery Disease: Risk Stratification and Clinical Decision Making. ( Anand, SS; Chan, N; Kaplovitch, E; McClure, GR, 2022)
"High-quality evidence from trials directly comparing single antiplatelet therapies in symptomatic peripheral arterial disease (PAD) to dual antiplatelet therapies or acetylsalicylic acid (ASA) plus low-dose rivaroxaban is lacking."5.22Antithrombotic Therapy for Symptomatic Peripheral Arterial Disease: A Systematic Review and Network Meta-Analysis. ( de Borst, GJ; Hannink, G; Kramers, K; Maas, DPMSM; Mees, BME; Reijnen, MMPJ; Riksen, NP; Ten Cate, H; van der Vijver-Coppen, RJ; Warlé, MC; Willems, LH; Zeebregts, CJ, 2022)
"PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis In Myocardial Infarction 54) randomized 21,162 patients with prior MI (1 to 3 years) to ticagrelor 90 mg twice daily, ticagrelor 60 mg twice daily, or placebo, all on a background of low-dose aspirin."5.22Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. ( Abola, MTB; Aylward, P; Bhatt, DL; Bonaca, MP; Braunwald, E; Cohen, M; Corbalán, R; Dalby, A; Dellborg, M; Goodrich, E; Held, P; Jensen, EC; Kuder, J; López-Sendón, J; Nicolau, JC; Parkhomenko, A; Sabatine, MS; Špinar, J; Steg, PG; Storey, RF, 2016)
"This study aims to evaluate whether cilostazol plus aspirin is more efficacious than aspirin alone for preventing progression of atherosclerosis in patients with ischemic stroke or transient ischemic attack (TIA) who also have peripheral arterial disease."5.20The efficacy and safety of cilostazol in ischemic stroke patients with peripheral arterial disease (SPAD): protocol of a randomized, double-blind, placebo-controlled multicenter trial. ( Chen, CH; Chen, ST; Chern, CM; Chiou, HY; Chiu, HC; Hsu, CY; Hu, HH; Jeng, JS; Lee, JT; Lien, LM; Lin, HJ; Lin, RT; Liu, CH; Ma, H; Po, HL; Sun, MC; Sun, MH; Sun, Y, 2015)
"Patients with PAD on ASA therapy at baseline were included from the ongoing Effect of Lipid Modification on Peripheral Arterial Disease after Endovascular Intervention Trial (ELIMIT), which is a randomized trial testing whether combination treatment with ezetimibe, niacin, and a statin will halt/regress atherosclerosis compared with statin monotherapy."5.15Variability and persistence of aspirin response in lower extremity peripheral arterial disease patients. ( Ballantyne, CM; Dong, JF; Kimball, KT; Lumsden, AB; Morrisett, JD; Nambi, V; Saunders, J; Virani, SS, 2011)
"The Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) trial was a prospective, randomized, open-label trial conducted throughout Japan that enrolled 2,539 type 2 diabetic patients without a history of atherosclerotic diseases."5.15Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular filtration rate: subanalysis from the JPAD trial. ( Akai, Y; Doi, N; Jinnouchi, H; Morimoto, T; Nakayama, M; Ogawa, H; Okada, S; Saito, Y; Soejima, H; Sugiyama, S; Uemura, S; Waki, M, 2011)
" aspirin and placebo on platelet aggregation in peripheral arterial disease (PAD) patients."5.14Thromboxane Antagonism with terutroban in Peripheral Arterial Disease: the TAIPAD study. ( Bounameaux, H; Cairols, MA; Clement, DL; Coccheri, S; Fiessinger, JN; Fletcher, JP; Hoffmann, U; Turpie, AG, 2010)
" Dual-antiplatelet therapy is the standard of care for secondary prevention in patients with acute coronary syndrome (ACS), whereas single antiplatelet therapy, generally with aspirin, is the standard of care for secondary prevention in stable patients with coronary artery disease (CAD), peripheral artery disease (PAD), or cerebrovascular disease."5.05Dual Pathway Inhibition for Vascular Protection in Patients with Atherosclerotic Disease: Rationale and Review of the Evidence. ( Angiolillo, DJ; Geisler, T; Heitmeier, S; Weitz, JI, 2020)
"The COMPASS trial demonstrated that in patients with stable atherosclerotic disease, very low-dose rivaroxaban, a direct factor Xa inhibitor, when combined with aspirin, reduced the rate of recurrent ischemic events, at the cost of increased bleeding."5.05Aspirin and low-dose rivaroxaban - the dual pathway concept in patients with stable atherosclerotic disease: a comprehensive review. ( Eisen, A; Parascandolo, E, 2020)
"Aspirin decreases the risk of recurrent thrombotic events in patients with coronary artery disease or peripheral artery disease but the risk of recurrent events remains high."5.01How can the results of the COMPASS trial benefit patients with coronary or peripheral artery disease in Poland? ( Eikelboom, JW; Guzik, TJ; Kruger, PC, 2019)
" Patients with mesenteric ischaemia caused by atherosclerosis should be evaluated concerning platelet antiaggregation with low dose aspirin or clopidogrel, and those with cardioembolic disease should be recommended anticoagulant treatment with either warfarin or one of the direct oral anticoagulants (DOAC; apixaban, dabigatran, edoxaban, or rivaroxaban)."4.95Pharmacological secondary prevention in patients with mesenterial artery atherosclerosis and arterial embolism. ( Gottsäter, A, 2017)
"Vorapaxar is a novel antiplatelet agent that has demonstrated efficacy in reducing atherosclerotic events in patients with a history of MI or PAD without a history of stroke, transient ischemic attack, or ICH when taken in combination with aspirin and clopidogrel."4.91Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease. ( Arif, SA; D'Souza, J; Gil, M; Gim, S, 2015)
"The use of aspirin is considered the "gold standard" for the decrease of major adverse cardiovascular events in patients with atherosclerosis, including peripheral arterial disease (PAD), whereas a dual-antiplatelet regimen with aspirin and clopidogrel is usually indicated for such patients after angioplasty and stent deployment."4.90High on-treatment platelet reactivity in peripheral endovascular procedures. ( Hatzidakis, A; Kassimis, G; Krokidis, M; Spiliopoulos, S, 2014)
" Of 2 treatment trials meeting inclusion criteria, 1 large trial (n = 3350) showed that low-dose aspirin did not prevent CVD events in persons with a screen-detected low ABI but may have increased the risk for major bleeding events."4.89The ankle-brachial index for peripheral artery disease screening and cardiovascular disease prediction among asymptomatic adults: a systematic evidence review for the U.S. Preventive Services Task Force. ( Johnson, ES; Lin, JS; Olson, CM; Whitlock, EP, 2013)
"To assess the clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole (MRD) alone or with aspirin (ASA) compared with ASA (and each other where appropriate) in the prevention of occlusive vascular events in patients with a history of MI, ischaemic stroke/TIA or established peripheral arterial disease."4.87Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis. ( Bagust, A; Blundell, M; Boland, A; Dickson, R; Dundar, Y; Fisher, M; Greenhalgh, J; Martin Saborido, C; Oyee, J; Proudlove, C, 2011)
" The currently available antiplatelet drugs used to prevent vascular events in patients with cardiovascular disease, including peripheral arterial disease (PAD), include aspirin and thienopyridines such as clopidogrel."4.86[The basis of platelets: platelets and atherothrombosis: an understanding of the lack of efficacy of aspirin in peripheral arterial disease (PAD) and diabetic patients]. ( Bal dit Sollier, C; Drouet, L; Henry, P, 2010)
"The innovative pharmacological combination of low-dose rivaroxaban plus aspirin provides clinicians with an ideal opportunity to intensify the medical treatment of patients with coronary artery disease (CAD) and comorbid peripheral artery disease (PAD)."4.31Cost-effectiveness analysis of screening for peripheral artery disease in patients with coronary artery disease in China: A Markov model. ( Qiu, Y; Wang, Y; Xing, Y; Yang, L; Yuan, Z, 2023)
"Dual pathway inhibition (DPI) with low-dose rivaroxaban and aspirin in patients with coronary artery disease (CAD) and/or peripheral artery disease (PAD) reduces the occurrence of cardiovascular (CV) events; however, the underlying mechanisms explaining these latter CV benefits are not clearly understood."4.31Dual Pathway Inhibition with Rivaroxaban and Aspirin Reduces Inflammatory Biomarkers in Atherosclerosis. ( Attena, E; Cotticelli, C; D'Alterio, G; D'Onofrio, A; Fabiani, D; Golino, P; Leonardi, S; Maione, B; Nigro, G; Rago, A; Russo, V; Sarpa, S, 2023)
"In unselected patients undergoing revascularization for peripheral arterial disease, the majority presents with characteristics that, at present, preclude prescription of rivaroxaban in addition to aspirin."4.12Prevalence of VOYAGER PAD trial exclusion criteria in unselected patients undergoing lower limb revascularization. ( Grassl, KJ; Klocker, J; Moll, CW; Moll, MA; Neururer, SB; Westreicher, W; Wipper, SH; Zwerger, D, 2022)
" This study aims to compare the impact of aspirin (ASA) monotherapy, P2Y12 monotherapy, and DAPT on limb salvage (LS), amputation-free survival (AFS), and overall survival (OS) in patients undergoing lower extremity peripheral endovascular intervention (PVI) for chronic limb-threatening ischemia (CLTI)."4.12P2Y12 inhibitor monotherapy is associated with superior outcomes as compared with aspirin monotherapy in chronic limb-threatening ischemia. ( Dosluoglu, HH; Dryjski, ML; Fakhoury, E; Harris, LM; Khan, SZ; Montross, B; O'Brien-Irr, MS; Rivero, M, 2022)
" The COMPASS trial has shown that in patients with stable coronary artery disease (CAD) or peripheral artery disease (PAD), low-dose rivaroxaban (2."4.12[ANMCO Position paper: Evidence and practical indications for the use of low-dose rivaroxaban in stable coronary artery disease and peripheral artery disease]. ( Altamura, V; Bianco, M; Caldarola, P; Ceravolo, R; Cipriani, M; Colivicchi, F; De Luca, L; Di Fusco, SA; Francese, GM; Gabrielli, D; Gulizia, MM; Lucà, F; Nardi, F; Navazio, A; Oliva, F; Riccio, C; Rizzello, V; Scicchitano, P; Valente, S, 2022)
"Background The COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trial decreased major adverse cardiovascular events with very low-dose rivaroxaban and aspirin in patients with coronary artery disease and peripheral artery disease."4.12Eligibility and Implementation of Rivaroxaban for Secondary Prevention of Atherothrombosis in Clinical Practice-Insights From the CANHEART Study. ( Abdel-Qadir, H; Chu, A; Farkouh, ME; Ferreira-Legere, LE; Goodman, SG; Ko, DT; Porter, J; Sheth, MS; Tam, DY; Udell, JA; Yu, B, 2022)
"This study aimed to investigate the cost-effectiveness of low-dose rivaroxaban plus aspirin versus aspirin alone for patients with stable cardiovascular diseases in the Taiwan setting."4.02Cost-effectiveness analysis of rivaroxaban plus aspirin versus aspirin alone in secondary prevention among patients with chronic cardiovascular diseases. ( Chang, WT; Chen, ZC; Chou, CC; Lee, MC; Liao, CT; Strong, C; Toh, HS; Wu, WS; Yu, T, 2021)
"5 mg twice daily) plus aspirin (100 mg once daily) with aspirin alone in patients with coronary artery disease (CAD) or peripheral artery disease (PAD) and related subgroups."4.02Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in Patients with Coronary and Peripheral Artery Diseases in Italy. ( Cortesi, PA; Di Laura, D; Ferrara, P; Maggioni, AP; Mantovani, LG, 2021)
"5 mg rivaroxaban twice daily plus 100 mg aspirin once daily may be a promising alternative to 100 mg aspirin antiplatelet therapy for the prevention of cardiovascular events in patients with coronary artery disease and/or peripheral arterial disease."3.96Rivaroxaban plus aspirin for the prevention of ischaemic events in patients with cardiovascular disease: a cost-effectiveness study. ( Joore, M; Petersohn, S; Pouwels, X; Ramaekers, B; Ten Cate-Hoek, A, 2020)
"A total of 176 patients taking antiplatelet medications aspirin and/or clopidogrel with peripheral artery disease (PAD) and/or carotid stenosis (CS) were included in the study."3.96Perioperative changes of response to antiplatelet medication in vascular surgery patients. ( Breuer-Kaiser, A; Düsterwald, JO; Hummel, T; Meves, SH; Mühlberger, D; Mumme, A; Neubauer, H, 2020)
"Circulating MPA are a robust marker of platelet activity and monocyte inflammation, unaffected by low-dose aspirin, and are significantly elevated in subjects with CVD, particularly those with PAD."3.91Circulating monocyte-platelet aggregates are a robust marker of platelet activity in cardiovascular disease. ( Allen, N; Barrett, TJ; Berger, JS; Guo, Y; Hochman, JS; Nardi, M; Ramkhelawon, B; Rockman, CB, 2019)
"In the COMPASS trial, combined aspirin and rivaroxaban treatment reduced ischaemic events in patients with stable coronary artery disease (CAD) or peripheral artery disease (PAD)."3.91External applicability of the COMPASS trial: the Western Denmark Heart Registry. ( Eikelboom, JW; Kristensen, SD; Maeng, M; Olesen, KKW; Thim, T; Würtz, M, 2019)
"The aims of the present study were to describe the proportion of patients eligible for the COMPASS trial within the Reduction of Atherothrombosis for Continued Health (REACH) registry, the reasons for ineligibility, and to put in perspective the characteristics and outcomes of trial-eligible patients from the REACH registry compared with those of patients enrolled in the reference aspirin arm of the COMPASS trial."3.88External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry. ( Aboyans, V; Abtan, J; Anand, S; Bhatt, DL; Bosch, J; Branch, KR; Connolly, SJ; Darmon, A; Ducrocq, G; Dyal, L; Eagle, KA; Eikelboom, JW; Elbez, Y; Fox, KAA; Keltai, K; Probstfield, J; Sorbets, E; Steg, PG; Yusuf, S, 2018)
"The goal of this study is to establish the prevalence of high on-treatment platelet reactivity to aspirin (HPRA) and clopidogrel (HPRC) in patients with critical limb ischemia (CLI)."3.88Prevalence of high on-treatment (aspirin and clopidogrel) platelet reactivity in patients with critical limb ischemia. ( Al-Asady, N; Caro, J; Clavijo, LC; Dhillon, A; Matthews, RV; Rowe, V; Shavelle, DM; Tun, H, 2018)
"Our aims were to examine the prevalence and genetic predictors of aspirin and clopidogrel high on-treatment platelet reactivity (HoTPR), and associated adverse cardiovascular outcomes in patients with peripheral arterial disease (PAD)."3.88Aspirin and clopidogrel high on-treatment platelet reactivity and genetic predictors in peripheral arterial disease. ( Amsterdam, EA; Anderson, D; Armstrong, EJ; Chen, DC; Chiamvimonvat, N; Hua, A; Laird, JR; Li, CS; López, JE; Singapuri, A; Westin, GG; Yeo, KK, 2018)
"To evaluate long-term health benefits and risks of adding vorapaxar (VOR) to the standard care antiplatelet therapy (SC) of aspirin and/or clopidogrel, among a population with a recent myocardial infarction (MI) and/or peripheral artery disease (PAD)."3.85State transition model: vorapaxar added to standard antiplatelet therapy to prevent thrombosis post myocardial infarction or peripheral artery disease. ( Chase, M; Davies, G; Du, M; Oguz, M, 2017)
"Restenosis and stent thrombosis after endovascular intervention in patients with peripheral arterial disease (PAD) can potentially be tackled by more intensive antiplatelet therapy, such as dual antiplatelet therapy (DAPT) consisting of aspirin and P2Y12 inhibitor."3.83High On-Treatment Platelet Reactivity in Peripheral Arterial Disease: A Pilot Study to Find the Optimal Test and Cut Off Values. ( Asselbergs, FW; de Borst, GJ; den Ruijter, HM; Leunissen, TC; Moll, FL; Peeters Weem, SM; Urbanus, RT, 2016)
"Current guidelines recommend antithrombotic therapy with either aspirin or clopidogrel for all patients with peripheral arterial disease (PAD)."3.81Adverse cardiovascular outcomes in relation to suboptimal antithrombotic therapy use in patients undergoing peripheral artery disease angioplasty: lost opportunities? ( Allon, IR; Apostolakis, S; Bodansky, DM; Lip, GY, 2015)
"This study was conducted to determine whether there is additive benefit of dual-antiplatelet therapy (DAPT) with aspirin (acetylsalicylic acid [ASA]) and clopidogrel compared with ASA monotherapy among patients with symptomatic peripheral arterial disease."3.81Association of dual-antiplatelet therapy with reduced major adverse cardiovascular events in patients with symptomatic peripheral arterial disease. ( Amsterdam, EA; Anderson, DR; Armstrong, EJ; Bang, H; Freischlag, JA; Laird, JR; Singh, GD; Yeo, KK, 2015)
"Clopidogrel or aspirin are indicated for patients with recent ischemic stroke (IS) or established peripheral artery disease (PAD)."3.81Clopidogrel versus aspirin in patients with recent ischemic stroke and established peripheral artery disease: an economic evaluation in a Chinese setting. ( Ben, H; Li, T; Liu, M; Wu, B; Xu, Z; Zhong, H, 2015)
"Current guidelines recommend that patients with peripheral arterial disease (PAD) cease smoking and be treated with aspirin, statin medications, and angiotensin-converting enzyme (ACE) inhibitors."3.80Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease. ( Amsterdam, EA; Anderson, D; Armstrong, EJ; Bang, H; Chen, DC; Laird, JR; McCoach, CE; Singh, S; Westin, GG; Yeo, KK, 2014)
" Patients with critical limb ischemia following stent thrombosis were included if dual antiplatelet therapy consisting of 100 mg aspirin and 75 mg clopidogrel per day had been administered over three months prior to enrollment."3.80Response to dual antiplatelet therapy in patients with peripheral artery occlusive disease suffering from critical limb ischemia. ( Baecker, C; Baro, D; Meybohm, P; Mutlak, H; Schmitz-Rixen, T; Wand, S; Weber, CF; Zacharowski, K, 2014)
"Clopidogrel, cilostazol, and aspirin were compared in terms of efficacy and safety for primary prevention of stroke in peripheral artery disease (PAD) patients."3.79Cilostazol for primary prevention of stroke in peripheral artery disease: a population-based longitudinal study in Taiwan. ( Chu, CY; Hsu, PC; Lai, WT; Lee, WH; Lin, TH; Sheu, SH; Su, HM; Voon, WC, 2013)
"The novel P2Y12 antagonist ticagrelor inhibits adenosine diphosphate (ADP)-induced platelet aggregation more potently than clopidogrel and reduces the incidence of myocardial infarction and total death in patients with an acute coronary syndrome (ACS)."3.79Ticagrelor improves peripheral arterial function in patients with a previous acute coronary syndrome. ( Erlinge, D; Larsson, J; Ohman, J; Salmi, H; Torngren, K, 2013)
"Patients with peripheral artery disease (PAD) following peripheral percutaneous transluminal angioplasty (PTA) with stent implantation are prone to stent thrombosis despite treatment with aspirin and clopidogrel."3.79Impaired responsiveness to clopidogrel and aspirin in patients with recurrent stent thrombosis following percutaneous intervention for peripheral artery disease. ( Frołow, M; Mazur, P; Niżankowski, R; Sadowski, J; Undas, A, 2013)
"Vorapaxar is a novel antiplatelet therapy that inhibits thrombin-mediated platelet aggregation to prevent recurrence of ischemic events."3.01Protease-Activated Receptor Antagonist for Reducing Cardiovascular Events - A Review on Vorapaxar. ( Aedma, SK; Combs, WG; Gupta, R; Kluck, B; Lin, M; Mehta, A; Patel, NC; Ranchal, P; Shah, R; Singh, S; Vyas, AV, 2023)
"In the VOYAGER PAD trial, rivaroxaban plus aspirin reduced the risk of adverse cardiovascular and limb events with an early benefit for acute limb ischemia regardless of clopidogrel use."2.94Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and Safety. ( Anand, SS; Bauersachs, R; Berkowitz, SD; Bonaca, MP; Brackin, T; Brasil, D; Capell, WH; Debus, ES; Haskell, L; Hess, CN; Hiatt, WR; Jaeger, N; Madaric, J; Muehlhofer, E; Nehler, MR; Pap, AF; Patel, MR; Sillesen, H; Szalay, D, 2020)
"We examined new cancers diagnosed in relation to gastrointestinal or genitourinary bleeding among patients enrolled in the COMPASS trial (Cardiovascular Outcomes for People Using Anticoagulation Strategies) and determined the hazard of new cancer diagnosis after bleeding at these sites."2.90Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis. ( Aboyans, V; Alings, M; Anand, SS; Avezum, A; Berkowitz, SD; Bhatt, DL; Bosch, J; Connolly, SJ; Cook-Bruns, N; Eikelboom, JW; Felix, C; Fox, KAA; Hart, RG; Maggioni, AP; Moayyedi, P; O'Donnell, M; Rydén, L; Shestakovska, O; Verhamme, P; Widimsky, P; Yusuf, S; Zhu, J, 2019)
" These drugs are well tolerated in the short term, but long-term treatment was associated with adverse events in observational studies."2.90Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. ( Alings, M; Anand, SS; Avezum, A; Bhatt, DL; Bosch, J; Branch, KRH; Bruns, NC; Commerford, PJ; Connolly, SJ; Dagenais, GR; Dans, AL; Diaz, R; Dyal, L; Eikelboom, JW; Ertl, G; Felix, C; Fox, KAA; Guzik, TJ; Hart, RG; Hori, M; Kakkar, AK; Keltai, M; Kim, JH; Lanas, F; Leong, D; Lewis, BS; Liang, Y; Lonn, EM; Lopez-Jaramillo, P; Maggioni, AP; Metsarinne, KP; Moayyedi, P; Muehlhofer, E; O'Donnell, M; Parkhomenko, AN; Piegas, LS; Pogosova, N; Probstfield, J; Ryden, L; Shestakovska, O; Steg, PG; Störk, S; Tonkin, AM; Torp-Pedersen, C; Verhamme, PB; Vinereanu, D; Widimsky, P; Yusoff, K; Yusuf, S; Zhu, J, 2019)
"Ticagrelor is a P2Y12 receptor antagonist with evidence of cardiovascular event reduction in patients with acute coronary syndromes and those with a previous myocardial infarction."2.87Ticagrelor and the Prevention of Microvascular Complications in Diabetes Patients with Lower Extremity Arterial Disease; Rationale and Design of the Hema-Kinesis Trial. ( Chen, Q; Cho, DJ; Lee, ML; Najera, SD; Rosenson, RS, 2018)
" Secondary outcomes include target lesion revascularization, major bleeding, ipsilateral major amputation, all-cause mortality, and all adverse events that take place in those six months."2.84SAFE (Sarpogrelate Anplone in Femoro-popliteal artery intervention Efficacy) study: study protocol for a randomized controlled trial. ( Ahn, S; Cho, MJ; Cho, S; Ha, J; Kim, SY; Lee, J; Min, SI; Min, SK, 2017)
"Cilostazol has been reported to reduce intimal hyperplasia and subsequent repeat revascularization."2.79Efficacy of two different self-expanding nitinol stents for atherosclerotic femoropopliteal arterial disease (SENS-FP trial): study protocol for a randomized controlled trial. ( Bae, JH; Baek, JY; Bong, JM; Cho, JH; Cho, YH; Choi, CU; Choi, HJ; Choi, SH; Choi, WG; Chung, WY; Her, SH; Kang, WY; Kim, EJ; Kim, JH; Kim, KC; Kim, MW; Kim, SM; Kim, WH; Kim, YH; Kim, YJ; Lee, SJ; Oh, DJ; Park, MW; Park, SH; Rha, SW; Seo, JB; Soh, JW; Suh, J, 2014)
"Secondary end points were the restenosis rate on duplex ultrasound, the rate of major adverse cardiac events, and target lesion event-free survival."2.78Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study. ( Hamasaki, T; Hirano, K; Iida, O; Inoue, N; Isshiki, T; Kawasaki, D; Miyamoto, A; Miyashita, Y; Nakamura, M; Nanto, S; Shinozaki, N; Shintani, Y; Soga, Y; Suzuki, K; Tsuchiya, T; Urasawa, K; Yokoi, H; Yokoi, Y; Zen, K, 2013)
" Efficacy (major adverse cardiovascular events, acute or chronic limb ischaemia, vascular amputation, peripheral revascularisation) and safety (all-cause mortality and overall bleeding) outcomes were evaluated via Bayesian network meta-analyses."2.72Efficacy and Safety of Antiplatelet Therapies in Symptomatic Peripheral Artery Disease: A Systematic Review and Network Meta-Analysis. ( Cimminiello, C; De Carlo, M; Di Minno, G; Fazeli, MS; Sayre, T; Siliman, G, 2021)
"Patients with lower extremity peripheral artery disease (PAD) are at increased risk of major adverse limb events (MALE)."2.72The efficacy and safety of direct oral anticoagulants plus aspirin in symptomatic lower extremity peripheral arterial disease: a systematic review and meta-analysis of randomized controlled trials. ( Costa, G; Gonçalves, L; Teixeira, R, 2021)
"Patients with peripheral artery disease are at high-risk for cardiovascular events."2.58[Anti-Thrombotic Treatment of Patients with Peripheral Artery Disease (PAD)]. ( Espinola-Klein, C, 2018)
"Peripheral artery disease is a common manifestation of systemic atherosclerosis which strongly correlates to cardiovascular morbidity and mortality."2.58Novel Oral Anticoagulants in Peripheral Artery Disease: Current Evidence. ( Argyriou, C; Georgakarakos, EI; Georgiadis, GS; Koutsoumpelis, A; Tasopoulou, KM, 2018)
"However, both trials revealed excess diplopia (double vision) usually reversible after vorapaxar."2.53Vorapaxar and diplopia: Possible off-target PAR-receptor mismodulation. ( Can, M; Fortmann, SD; Hanley, DF; Kim, MH; Lordkipanidze, M; Marciniak, TA; Rao, SV; Serebruany, VL; Tanguay, JF, 2016)
"In the peripheral arteries, a thrombus superimposed on atherosclerosis contributes to the progression of peripheral artery disease (PAD), producing intermittent claudication (IC), ischemic necrosis, and, potentially, loss of the limb."2.50Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease. ( Cafaro, G; de Gaetano, G; Di Minno, A; Di Minno, G; Lupoli, R; Petitto, M; Spadarella, G; Tremoli, E, 2014)
"After the procedure, deep vein thrombosis (DVT) was a commonly diagnosed complication (3."1.91Incidence of venous thromboembolism in patients with peripheral arterial disease after endovascular intervention. ( Agala, C; Caruso, DM; Duchesneau, E; Farber, M; Kindell, DG; Marston, WA; Marulanda, K; McGinigle, KL, 2023)
"Peripheral artery disease affects 1."1.51Cost-effectiveness of low-dose rivaroxaban and aspirin versus aspirin alone in people with peripheral or carotid artery disease: An Australian healthcare perspective. ( Ademi, Z; Hird, TR; Liew, D; Owen, AJ; Reid, CM; Si, S; Tonkin, A; Zomer, E, 2019)
"Most parameters of thrombus formation under flow were similarly high for the patient and control groups."1.42Normal platelet activation profile in patients with peripheral arterial disease on aspirin. ( Baaten, CC; Clemetson, KJ; Cosemans, JM; de Laat, B; Heemskerk, JW; Kleinegris, MC; Roest, M; Ten Cate, H; van Geffen, JP; Verdoold, R, 2015)
"Atorvastatin 80 mg was found to be independent predictor of survival, and major amputation was found to be independent predictor of mortality."1.39Long-term results of plaque excision combined with aggressive pharmacotherapy in high-risk patients with advanced peripheral artery disease (SAVE a LEG registry). ( Buszman, PE; Buszman, PP; Kiesz, RS; Konkolewska, MD; Martin, JL; Radvany, MG; Szymanski, R; Wiernek, BK; Wiernek, SL, 2013)
"Peripheral arterial disease is a manifestation of systemic atherosclerosis and is predictive of future cardiovascular events."1.38The quality and impact of risk factor control in patients with stable claudication presenting for peripheral vascular interventions. ( Ardati, AK; Aronow, HD; Bove, PG; Grossman, PM; Gurm, HS; Kaufman, SR; Nypaver, TJ, 2012)
"Atherosclerosis is a chronic inflammatory disease of the vessel wall."1.36Aspirin-triggered lipoxin and resolvin E1 modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis. ( Conte, MS; Creager, MA; Ho, KJ; Kroemer, AH; Lancero, H; Owens, CD; Pande, R; Serhan, CN; Spite, M, 2010)

Research

Studies (222)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's127 (57.21)24.3611
2020's95 (42.79)2.80

Authors

AuthorsStudies
Anand, SS26
Hiatt, W1
Dyal, L6
Bauersachs, R4
Berkowitz, SD21
Branch, KRH7
Debus, S4
Fox, KAA18
Liang, Y5
Muehlhofer, E20
Nehler, M3
Haskell, LP10
Patel, M2
Szarek, M8
Yusuf, S21
Eikelboom, J4
Bonaca, MP16
Zhang, J1
Vallabhaneni, SR2
Lip, GYH2
Basili, S2
Romiti, GF1
Cangemi, R1
Corica, B1
Wu, O1
Hawkins, N1
Bowrin, K2
Wojciechowski, P1
Clay, E1
Huelsebeck, M1
Kotalczyk, A1
Coleman, CI1
Kharat, AA1
Bookhart, B1
Baker, WL1
Gupta, R3
Lin, M2
Mehta, A2
Aedma, SK1
Shah, R1
Ranchal, P1
Vyas, AV1
Singh, S2
Kluck, B1
Combs, WG1
Patel, NC1
Li, W1
Zhang, H1
Xiang, Q1
Cui, Y1
Kawashima, H1
Serruys, PW1
Wang, R1
Lunardi, M1
Onuma, Y1
Moll, MA1
Zwerger, D1
Grassl, KJ1
Westreicher, W1
Neururer, SB1
Moll, CW1
Wipper, SH1
Klocker, J1
Søgaard, M1
Nielsen, PB1
Skjøth, F1
Larsen, TB1
Eldrup, N1
Golledge, J1
Marcaccio, CL1
Patel, PB1
Wang, S1
Rastogi, V1
Moreira, CC1
Siracuse, JJ1
Schermerhorn, ML2
Stangenberg, L1
Bauersachs, RM10
Nehler, MR9
Debus, ES10
Patel, MR13
Capell, WH9
Hess, CN9
Hsia, J4
Leeper, NJ1
Brasil, D2
Mátyás, L3
Diaz, R6
Brodmann, M4
McClure, GR2
Kaplovitch, E3
Chan, N1
Eikelboom, JW21
Bosch, J17
Connolly, SJ18
Tyrwitt, J1
Neumann, C1
Tasto, C2
Bangdiwala, SI4
Alings, M7
Dagenais, GR7
Leong, DP4
Lonn, EM2
Avezum, A8
Piegas, LS2
Widimsky, P7
Parkhomenko, AN2
Bhatt, DL20
Probstfield, JL4
Lopez-Jaramillo, P3
Rydén, L5
Pogosova, N4
Keltai, K5
Keltai, M2
Ertl, G3
Stoerk, S1
Dans, AL2
Lanas, F2
Zhu, J6
Torp-Pedersen, C2
Maggioni, AP10
Commerford, PJ3
Guzik, TJ5
Vanassche, T3
Verhamme, P6
O'Donnell, M7
Tonkin, AM2
Varigos, JD2
Vinereanu, D3
Felix, C4
Kim, JH3
Ibrahim, KS1
Lewis, BS3
Metsarinne, KP3
Aboyans, V16
Steg, PG7
Hori, M3
Kakkar, A1
Lamy, A3
Sharma, M3
Zeymer, U2
Cowie, MR3
Welsh, RC1
Gay, A2
Vogtländer, K2
Majumdar, M3
Imran, R1
Yi, J1
Baumgartner, I3
Capell, W1
Khan, SZ1
O'Brien-Irr, MS1
Fakhoury, E1
Montross, B1
Rivero, M1
Dosluoglu, HH1
Harris, LM1
Dryjski, ML1
Shestakovska, O11
Beckman, JA2
Piazza, G1
Henkin, S1
Bura-Rivière, A2
Lawall, H1
Roztocil, K1
Maggioni, A2
Goto, S2
Kranendonk, J1
Willems, LH2
Vijver-Coppen, RV1
Coenen, M1
Adang, E1
Donders, R1
Zeebregts, CJ2
Deneer, V1
Reijnen, M1
Kramers, C1
Warlé, MC2
Maas, DPMSM1
Kramers, K1
Reijnen, MMPJ1
Riksen, NP1
Ten Cate, H3
van der Vijver-Coppen, RJ1
de Borst, GJ3
Mees, BME1
Hannink, G1
Tong, W1
Yuan, F1
Connolly, S2
Lonn, E1
Wang, WJ1
Probstfield, J3
Störk, S3
Durand-Zaleski, I1
Waller, D1
Poyant, J1
McElroy, I1
Lella, S1
Feldman, ZM1
Levine, E1
Kim, Y1
Nuzzolo, K1
Kirshkaln, A1
DeCarlo, C1
Dua, A2
Adik-Pathak, L1
Shirodkar, S1
Gupta, A1
Kindell, DG1
Marulanda, K1
Caruso, DM1
Duchesneau, E1
Agala, C1
Farber, M1
Marston, WA1
McGinigle, KL1
De Carlo, M3
Schlager, O1
Mazzolai, L2
Espinola-Klein, C4
Staub, D1
Sillesen, H4
Venermo, M1
Belch, J1
Ferrari, M1
De Caterina, R2
Xing, Y1
Qiu, Y1
Yang, L1
Yuan, Z1
Wang, Y2
Hayashi, N1
Matsuyama, Y1
Fujiwara, T1
Govsyeyev, N3
Conte, MS4
Chung, J2
Dorigo, W2
Gudz, I3
Krievins, D3
Mills, J3
Moll, F3
Norgren, L2
Piffaretti, G3
Powell, R2
Szalay, D3
Wohlauer, M2
Jaeger, N5
Di Fusco, SA2
Rizzello, V2
Scicchitano, P2
Lucà, F2
Altamura, V2
Bianco, M2
De Luca, L3
Valente, S2
Riccio, C2
Caldarola, P2
Cipriani, M2
Francese, GM2
Navazio, A2
Nardi, F2
Ceravolo, R2
Gulizia, MM2
Gabrielli, D2
Oliva, F2
Colivicchi, F2
Sheth, MS2
Yu, B2
Chu, A2
Porter, J2
Tam, DY2
Ferreira-Legere, LE2
Goodman, SG2
Farkouh, ME2
Ko, DT2
Abdel-Qadir, H2
Udell, JA2
Carlin, S1
de Vries, TAC2
Budaj, A1
Russo, V1
Fabiani, D1
Leonardi, S1
Attena, E1
D'Alterio, G1
Cotticelli, C1
Rago, A1
Sarpa, S1
Maione, B1
D'Onofrio, A1
Golino, P1
Nigro, G1
Yi, Q1
Han, A1
Lee, T1
Lee, J2
Song, SW1
Lee, SS1
Jung, IM1
Kang, JM1
Gwon, JG1
Yun, WS1
Cho, YP1
Ko, H1
Park, YJ1
Min, SK2
Li, LG1
Ma, X1
Qadura, M1
Syed, MH1
Anand, S2
Weissler, EH1
Stebbins, A1
Wruck, L1
Muñoz, D1
Gupta, K1
Girotra, S1
Whittle, J1
Benziger, CP1
Polonsky, TS1
Bradley, SM1
Hammill, BG1
Merritt, JG1
Zemon, DN1
Hernandez, AF1
Jones, WS3
Matheny, H1
O'Banion, LA1
Spaccarotella, C1
Simonetti, F1
Piccolo, R2
Esposito, G1
Suarez Ferreira, SP1
Hall, RP1
Goudot, G1
Jessula, S1
Bellomo, T1
Lee, I1
Kukreja, N1
Parmar, G1
Boada, AE1
Kokkinidis, DG1
Schizas, D1
Pargaonkar, S1
Karamanis, D1
Mylonas, KS1
Hasemaki, N1
Palaiodimos, L1
Varrias, D1
Tzavellas, G1
Siasos, G1
Klonaris, C1
Kharawala, A1
Chlorogiannis, DD1
Georgopoulos, S1
Bakoyiannis, C1
Cleland, JGF1
Pellicori, P1
Narula, S1
Bhagirath, VC1
Cook-Bruns, N2
Hart, RG7
Moayyedi, P2
Bosch, JJ2
Cairns, JA1
Cook Bruns, N1
Bode, C1
Olivier, CB1
Duerschmied, D1
Hardung, D1
Behne, A1
Langhoff, R1
Fox, KA2
Levy, P1
Mealing, S1
Millier, A1
Mernagh, P1
Cristeau, O1
Briere, JB1
Lin, Z1
Zhang, L1
Yang, X1
Liu, L2
Xuan, J1
Monje, D1
Lawatscheck, R1
Tantry, U2
Cummings, C1
Mackrell, P1
Gonze, M1
Ulloa, K1
Bafford, R1
Rout, A1
Sukhi, A1
Gurbel, P1
Fanelli, F3
Diao, L1
Pap, AF2
Kittelson, JM2
Krievins, DK2
Hiatt, WR10
Petersohn, S1
Pouwels, X1
Ramaekers, B1
Ten Cate-Hoek, A1
Joore, M1
Keller, L1
Chiarito, M1
Sanz-Sánchez, J1
Cannata, F1
Cao, D1
Sturla, M1
Panico, C1
Godino, C1
Regazzoli, D1
Reimers, B1
Condorelli, G1
Ferrante, G2
Stefanini, GG1
Weitz, JI4
Angiolillo, DJ1
Geisler, T1
Heitmeier, S1
Barbarash, OL1
Kashtalap, VV1
Marone, EM1
Rinaldi, LF1
Chierico, S1
Marazzi, G1
Palmieri, P1
Lovotti, M1
Klersy, C1
Ameriso, SF1
Amarenco, P1
Pearce, LA1
Perera, KS1
Ntaios, G1
Lang, W1
Bereczki, D1
Uchiyama, S1
Kasner, SE1
Yoon, BW1
Lavados, P1
Firstenfeld, A1
Mikulik, R1
Povedano, GP1
Ferrari, J1
Mundl, H1
Colak, B1
Orhan, A1
Ece, I1
Yormaz, S1
Yilmaz, H1
Sahin, M1
Biagioni, RB1
Lopes, RD1
Agati, LB1
Sacilotto, R1
Wolosker, N1
Sobreira, ML1
de Freitas Soares, BL1
Joviliano, EE1
Bernardi, WH1
Junior, VC1
Caffaro, RA1
Fioranelli, A1
Van Bellen, B1
Casella, IB1
Fidelis, RJR1
Flumignan, RLG1
Comerota, AJ1
Ramacciotti, E1
Parascandolo, E1
Eisen, A1
Sperling, LS1
Wells, BJ1
Darmon, A3
Elbez, Y2
Abtan, J2
Mas, JL1
Cacoub, P1
Montalescot, G1
Billaut-Laden, I1
Ducrocq, G3
Singh, N1
Ding, L1
Magee, GA1
Shavelle, DM2
Kashyap, VS3
Garg, PK1
Lanthier, L1
Huard, G1
Plourde, ME1
Cauchon, M1
Di Minno, G2
Sayre, T1
Fazeli, MS1
Siliman, G1
Cimminiello, C1
Kataruka, A1
Mahtta, D1
Akeroyd, JM1
Hira, RS1
Kazi, DS1
Spertus, JA1
Petersen, LA1
Ballantyne, CM2
Virani, SS2
Lee, MC1
Liao, CT1
Toh, HS1
Chou, CC1
Chang, WT1
Chen, ZC1
Wu, WS1
Yu, T1
Strong, C1
Abola, MT2
Brackin, T2
Haskell, L2
Madaric, J1
Gebauer, K1
Wintersohl, K1
Kraska, R1
Kortendick, K1
Fahrland, U1
Freisinger, E1
Meyborg, M1
Stella, J1
Engelbertz, C1
Reinecke, H1
Malyar, N1
Ultee, KHJ1
Steunenberg, SL1
Schouten, O1
Gremmel, T2
Farber, A1
Hummel, T2
Meves, SH2
Breuer-Kaiser, A1
Düsterwald, JO1
Mühlberger, D1
Mumme, A2
Neubauer, H2
Costa, G1
Gonçalves, L1
Teixeira, R1
Ferrara, P1
Cortesi, PA1
Di Laura, D1
Mantovani, LG1
Poredos, P2
Antignani, PL1
Blinc, A1
Fras, Z1
Jezovnik, MK2
Fareed, J1
Mansilha, A1
Grachev, VG1
Vedenskaya, SS1
Smolenskaya, OG1
Giannopoulos, S1
Armstrong, EJ6
Winkelmann, BR1
Hamburg, NM1
Creager, MA3
Rivera-Caravaca, JM1
Camelo-Castillo, A1
Ramírez-Macías, I1
Gil-Pérez, P1
López-García, C1
Esteve-Pastor, MA1
Orenes-Piñero, E1
Tello-Montoliu, A1
Marín, F1
Lapébie, FX1
Lacroix, P1
Constans, J1
Boulon, C1
Messas, E1
Ferrières, J1
Bongard, V1
Hinterreiter, F1
Nault, P2
Svetlikov, A1
Sillesen, HH1
Conte, M1
Krantz, MJ1
Debus, SE1
Bracken, T1
Stefanov, S1
Ambler, GK1
Nordanstig, J1
Behrendt, CA1
Twine, CP1
Gottsäter, A1
Van de Werf, F1
Secemsky, EA1
Yeh, RW1
Kereiakes, DJ1
Cutlip, DE1
Massaro, JM1
Apruzzese, PK1
Mauri, L1
Brass, EP2
Guirgis, M1
Thompson, P1
Jansen, S1
Ahn, S1
Ha, J1
Min, SI1
Kim, SY1
Cho, MJ1
Cho, S1
Kakkar, AK2
Misselwitz, F1
Avezum, AA1
Chen, E2
Branch, K1
Faltado, AL1
Sandoval, MAS1
Kaw, L1
Branch, KR2
Sorbets, E1
Eagle, KA1
Clavijo, LC1
Al-Asady, N1
Dhillon, A1
Matthews, RV1
Caro, J1
Tun, H1
Rowe, V1
Yeo, KK3
López, JE1
Chen, DC4
Westin, GG2
Li, CS1
Anderson, D2
Hua, A1
Singapuri, A1
Amsterdam, EA5
Chiamvimonvat, N1
Laird, JR5
Caron, F1
Lanius, V1
Jaff, M2
Nwachuku, C1
Tangelder, M1
Ansel, G2
Adams, G2
Zeller, T3
Rundback, J1
Grosso, M2
Mercur, MF1
Minar, E2
Henni, S1
Ouedraogo, N1
Abraham, P1
Rogers, RK1
Shishehbor, MH2
White, R1
Khan, ND1
Bhalla, NP1
Low Wang, CC1
Gibler, WB1
Beiswenger, AC2
Jo, A2
Harth, K1
Kumins, NH1
Shatila, W1
Krajcer, Z1
Guirguis-Blake, JM1
Evans, CV1
Redmond, N1
Lin, JS2
Curry, SJ1
Krist, AH1
Owens, DK1
Barry, MJ1
Caughey, AB1
Davidson, KW1
Doubeni, CA1
Epling, JW1
Kemper, AR1
Kubik, M1
Landefeld, CS1
Mangione, CM1
Silverstein, M1
Simon, MA1
Tseng, CW1
Wong, JB1
Navarese, EP1
Wernly, B1
Lichtenauer, M1
Petrescu, AM1
Kołodziejczak, M1
Lauten, A1
Frediani, L1
Veulemanns, V1
Wanha, W1
Wojakowski, W1
Lesiak, M1
Zeus, T1
Bliden, K1
Buffon, A1
Contegiacomo, G1
Jung, C1
Kubica, J1
Pestrichella, V1
Gurbel, PA2
Rosenson, RS1
Chen, Q1
Najera, SD1
Lee, ML1
Cho, DJ1
Kruger, PC2
Boden, WE1
Xiang, Y1
Wang, J2
Zhao, J1
Huang, B1
Shlofmitz, E1
Garcia-Garcia, HM1
Zomer, E1
Si, S1
Hird, TR1
Liew, D1
Owen, AJ1
Tonkin, A2
Reid, CM1
Ademi, Z1
Koutsoumpelis, A1
Argyriou, C1
Tasopoulou, KM1
Georgakarakos, EI1
Georgiadis, GS1
Tsilimigras, DI1
Moris, D1
Karaolanis, G1
Kakkos, SK1
Filis, K1
Sigala, F1
Ng, KKH1
Catanese, L1
Ha, JW1
Varigos, J1
Fox, K1
Bruns, NC2
Allen, N1
Barrett, TJ1
Guo, Y1
Nardi, M1
Ramkhelawon, B1
Rockman, CB1
Hochman, JS1
Berger, JS2
Chan, NC1
Coppens, M1
Eikelboom, JWA1
Würtz, M1
Olesen, KKW1
Thim, T1
Kristensen, SD1
Maeng, M1
Tantry, US1
Leong, D1
Verhamme, PB1
Yusoff, K1
Cheng, RK1
Thomas, R1
Lee, WH1
Chu, CY1
Hsu, PC1
Su, HM1
Lin, TH1
Voon, WC1
Lai, WT1
Sheu, SH1
Gassman, AA1
Degner, BC1
Al-Nouri, O1
Philippi, L1
Hershberger, R1
Halandras, P1
Aulivola, B1
Milner, R1
Endres, HG1
Mayböck, N1
Kaiser, AF1
Schröder, KD1
Rüdiger, K1
Overbeck, U1
Mügge, A1
Torpy, JM1
Livingston, EH1
Torngren, K1
Ohman, J1
Salmi, H1
Larsson, J1
Erlinge, D1
Iida, O1
Yokoi, H1
Soga, Y1
Inoue, N1
Suzuki, K1
Yokoi, Y1
Kawasaki, D1
Zen, K1
Urasawa, K1
Shintani, Y1
Miyamoto, A1
Hirano, K1
Miyashita, Y1
Tsuchiya, T1
Shinozaki, N1
Nakamura, M1
Isshiki, T1
Hamasaki, T1
Nanto, S1
Spiliopoulos, S1
Kassimis, G1
Hatzidakis, A1
Krokidis, M1
Sobieszczyk, P1
Eisenhauer, A1
Olson, CM1
Johnson, ES1
Whitlock, EP1
Moyer, VA1
Strobl, FF2
Brechtel, K2
Schmehl, J2
Reiser, MF1
Claussen, CD2
Tepe, G2
Xhelili, E1
Steiner, S1
Koppensteiner, R2
Kopp, CW1
Panzer, S1
Guo, X1
Ma, H2
Hao, X1
Li, J1
McCoach, CE1
Bang, H2
Kuznetsov, MR2
Sergeeva, NA1
Koshkin, VM2
Boldin, BV1
Rodionov, SV2
Virganskiĭ, AO2
Kosykh, IV2
Lisenkov, OP2
Kuznetsova, VF1
George, JC1
Rosen, ES1
Nachtigall, J1
VanHise, A1
Kovach, R1
Bodansky, DM1
Allon, IR1
Apostolakis, S1
Lip, GY1
Spadarella, G1
Cafaro, G1
Petitto, M1
Lupoli, R1
Di Minno, A1
de Gaetano, G1
Tremoli, E1
Azarbal, A1
Clavijo, L1
Gaglia, MA1
Park, SH1
Rha, SW1
Choi, CU1
Kim, EJ1
Oh, DJ1
Cho, YH1
Choi, WG1
Lee, SJ1
Kim, YH1
Choi, SH1
Kim, WH1
Kim, KC1
Cho, JH1
Kim, SM1
Bae, JH1
Bong, JM1
Kang, WY1
Baek, JY1
Seo, JB1
Chung, WY1
Park, MW1
Her, SH1
Suh, J1
Kim, MW1
Kim, YJ1
Choi, HJ1
Soh, JW1
Weisel, RD1
Nussmeier, N1
Newman, MF1
Pearl, RG1
Wechsler, AS1
Ambrosio, G1
Pitt, B1
Clare, RM1
Pieper, KS1
Mongero, L1
Reece, TL1
Yau, TM1
Fremes, S1
Menasché, P1
Lira, A1
Harrington, RA1
Ferguson, TB1
Muendlein, A1
Kinz, E1
Gasser, K1
Leiherer, A1
Rein, P1
Saely, CH1
Grallert, H1
Peters, A1
Fraunberger, P1
Drexel, H1
Lang, AH1
Jeng, JS1
Sun, Y1
Lee, JT1
Lin, RT1
Chen, CH1
Po, HL1
Lin, HJ1
Liu, CH1
Sun, MH1
Sun, MC1
Chern, CM1
Lien, LM1
Chiu, HC1
Hu, HH1
Chiou, HY1
Chen, ST1
Hsu, CY1
Schmit, K1
Dolor, RJ1
Vemulapalli, S1
Hasselblad, V1
Subherwal, S1
Heidenfelder, B1
Clement, D1
van Bortel, L1
van Sambeek, MR1
Vlachopoulos, C1
van Geffen, JP1
Kleinegris, MC1
Verdoold, R1
Baaten, CC1
Cosemans, JM1
Clemetson, KJ1
Roest, M2
de Laat, B1
Heemskerk, JW1
Wand, S1
Baro, D1
Baecker, C1
Meybohm, P1
Schmitz-Rixen, T1
Zacharowski, K1
Mutlak, H1
Weber, CF1
Singh, GD3
Tangelder, MJ2
Nwachuku, CE1
Duggal, A1
Mercuri, M1
Shi, M1
Moll, FL4
Bleda, S1
De Haro, J1
Varela, C1
Ferruelo, A1
Acin, F1
Anderson, DR1
Freischlag, JA1
Li, T1
Liu, M1
Ben, H1
Xu, Z1
Zhong, H1
Wu, B1
Wisman, PP1
Teraa, M1
Verhaar, MC1
Sennesael, AL1
Dogné, JM1
Spinewine, A1
Qian, J1
Yang, XH1
Arif, SA1
D'Souza, J1
Gil, M1
Gim, S1
Hu, P1
Jones, S1
Serebruany, VL1
Fortmann, SD1
Rao, SV1
Tanguay, JF1
Lordkipanidze, M1
Hanley, DF1
Can, M1
Kim, MH1
Marciniak, TA1
Storey, RF1
Cohen, M1
Kuder, J1
Goodrich, E1
Nicolau, JC1
Parkhomenko, A1
López-Sendón, J1
Dellborg, M1
Dalby, A1
Špinar, J1
Aylward, P1
Corbalán, R1
Abola, MTB1
Jensen, EC1
Held, P1
Braunwald, E1
Sabatine, MS1
Bernlochner, I1
Jaitner, J1
Fries, V1
Dommasch, M1
Mayer, K1
Ott, I1
Langwieser, N1
Fusaro, M1
Laugwitz, KL1
Kastrati, A1
Ibrahim, T1
Fromonot, J1
Dignat-Georges, F1
Rossi, P1
Mottola, G1
Kipson, N1
Ruf, J1
Bonello, L1
Guieu, R1
Paganelli, F1
Leunissen, TC1
Peeters Weem, SM1
Urbanus, RT1
den Ruijter, HM1
Asselbergs, FW1
Franzone, A1
Gargiulo, G1
Ariotti, S1
Marino, M1
Santucci, A1
Baldo, A1
Magnani, G1
Moschovitis, A1
Windecker, S1
Valgimigli, M1
Soden, PA1
Zettervall, SL1
Ultee, KH1
Landon, BE1
O'Malley, AJ1
Goodney, PP2
DeMartino, RR1
Arya, S1
Pasala, T1
Hoo, JS1
Lockhart, MK1
Waheed, R1
Sengodan, P1
Alexander, J1
Gandhi, S1
Thott, O1
Granath, F1
Malmstedt, J1
Wahlgren, CM1
Waldo, SW1
Du, M1
Chase, M1
Oguz, M1
Davies, G1
Kirtane, AJ1
Ozan, MO1
Witzenbichler, B1
Rinaldi, MJ1
Metzger, DC1
Weisz, G1
Stuckey, TD1
Brodie, BR1
Mehran, R1
Ben-Yehuda, O1
Stone, GW1
Ho, KJ1
Spite, M1
Owens, CD1
Lancero, H1
Kroemer, AH1
Pande, R1
Serhan, CN1
Fiessinger, JN1
Bounameaux, H1
Cairols, MA1
Clement, DL1
Coccheri, S1
Fletcher, JP1
Hoffmann, U1
Turpie, AG1
Rhee, SY1
Kim, YS1
Chon, S1
Oh, S1
Woo, JT1
Kim, SW1
Kim, JW1
Soejima, H2
Morimoto, T2
Saito, Y2
Ogawa, H2
Drouet, L1
Bal dit Sollier, C1
Henry, P1
van Hattum, ES1
Lawson, JA1
Algra, A1
Saunders, J1
Nambi, V1
Kimball, KT1
Morrisett, JD1
Lumsden, AB1
Dong, JF1
Nakayama, M1
Uemura, S1
Doi, N1
Jinnouchi, H1
Waki, M1
Sugiyama, S1
Okada, S1
Akai, Y1
Stone, DH1
Schanzer, A1
Nolan, BW1
Adams, JE1
Powell, RJ1
Walsh, DB1
Cronenwett, JL1
Pande, RL1
Perlstein, TS1
Greenhalgh, J1
Bagust, A1
Boland, A1
Martin Saborido, C1
Oyee, J1
Blundell, M1
Dundar, Y1
Dickson, R1
Proudlove, C1
Fisher, M1
Duschek, N1
Vafaie, M1
Skrinjar, E1
Hirsch, K1
Waldhör, T1
Hübl, W1
Bergmayr, W1
Knoebl, P1
Assadian, A1
van der Loo, B1
Braun, J1
Golosnitskiĭ, PIu1
Tepliakov, SA1
Ostapchuk, NA1
Chernikov, VP1
Kamusella, P1
Wissgott, C1
Andresen, R1
Mazur, P1
Frołow, M1
Niżankowski, R1
Sadowski, J1
Undas, A1
Bantleon, R1
Violi, F1
Bötticher, G1
Gäbel, G1
Weiss, N1
Saeger, HD1
Bergert, H1
Rana, H1
Andrews, JS1
Chacko, BG1
Hansen, KJ1
Levy, PJ1
Kiesz, RS1
Wiernek, SL1
Wiernek, BK1
Radvany, MG1
Buszman, PP1
Szymanski, R1
Konkolewska, MD1
Martin, JL1
Buszman, PE1
Hanna, EB1
Ardati, AK1
Kaufman, SR1
Aronow, HD1
Nypaver, TJ1
Bove, PG1
Gurm, HS1
Grossman, PM1

Clinical Trials (38)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease (COMPASS - Cardiovascular OutcoMes for People Using Anticoagulation StrategieS).[NCT01776424]Phase 327,395 participants (Actual)Interventional2013-02-28Completed
An International, Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Trial Investigating the Efficacy and Safety of Rivaroxaban to Reduce the Risk of Major Thrombotic Vascular Events in Patients With Symptomatic Peripheral Artery Disease Un[NCT02504216]Phase 36,564 participants (Actual)Interventional2015-08-18Completed
HELicobacter Pylori Screening to Prevent Gastrointestinal Bleeding in Patients With Acute Myocardial Infarction Trial Based on the SWEDEHEART Registry (HELP-SWEDEHEART)[NCT05024864]22,000 participants (Anticipated)Interventional2021-11-17Recruiting
Xarelto + Acetylsalicylic Acid: Treatment Patterns and Outcomes in Patients With Atherosclerosis. A Non-interventional Study[NCT03746275]5,798 participants (Actual)Observational2018-11-13Completed
Synergistic Influence of Rivaroxaban on Inflammation and Coagulation Biomarkers in Patients With CAD and PAD on Aspirin Therapy[NCT04059679]Phase 430 participants (Anticipated)Interventional2020-01-30Recruiting
Safety and Efficacy of Century Clot-Guided Prophylactic Rivaroxaban Therapy for Post ST-Segment Elevation Myocardial Infarction Complicating Left Ventricular Thrombus Compared With Conventional Antiplatelet Therapy[NCT06013020]Phase 4374 participants (Anticipated)Interventional2023-08-28Recruiting
Efficacy and Safety of Apixaban in Reducing Restenosis and Limb Loss in Subjects With Symptomatic Peripheral Artery Disease (PAD) Undergoing Infrapopliteal Endovascular Peripheral Revascularization Procedures in Patients With Critical Limb[NCT04229264]Phase 3200 participants (Anticipated)Interventional2020-01-09Recruiting
SAFE (Sarpogrelate Anplone in Femoro-popliteal Artery Intervention Efficacy) Study : a Randomized Controlled Trial[NCT02959606]Phase 4272 participants (Anticipated)Interventional2016-12-31Recruiting
Influence of Rivaroxaban 2.5 mg Two Times a Day for Intermittent Claudication and Exercise Tolerance in Patients With Symptomatic Peripheral Arterial Disease (PAD) - a Randomised Controlled Trial[NCT04305028]100 participants (Anticipated)Observational2021-03-10Not yet recruiting
DUAL Pathway Inhibition (Low-dose Rivaroxaban and Aspirin) as Compared to Aspirin Only to Improve Endothelial Function in Peripheral Artery Disease.[NCT04218656]Phase 4159 participants (Actual)Interventional2020-06-08Completed
Registry Dedicated to Assess the Risk of Ischemic and Hemorrhagic Complications of Long-term Antithrombotic Therapy in Patients With Chronic Coronary Syndromes[NCT04347200]2,000 participants (Anticipated)Observational [Patient Registry]2015-01-15Recruiting
A Randomized, Open-Label, Parallel-Group, Multi-Center Study Of Adding Edoxaban Or Clopidogrel To Aspirin To Maintain Patency In Subjects With Peripheral Arterial Disease Following Femoropopliteal Endovascular Intervention[NCT01802775]Phase 2203 participants (Actual)Interventional2013-02-06Completed
A Phase II Multicentre, Randomised, Double-Blind, Controlled, Parallel-Group Study to Evaluate the Walking Time Effect of Long-Term Ticagrelor in Comparison to Long-Term Aspirin Administration in Ambulatory Patients With Peripheral Artery Disease Undergoi[NCT02227368]Phase 240 participants (Actual)Interventional2014-10-20Terminated
Health Program for prEvention of cardiovascuLar disEases Based on a Risk screeNing Strategy With Ankle-brachial Index.[NCT05884840]54,000 participants (Anticipated)Interventional2023-11-20Recruiting
Antiplatelet Resistance Research in Patients With Peripheral Arterial Revascularization[NCT03953547]88 participants (Actual)Observational2018-01-01Completed
OCT Evaluation of Early Vascular Repair in Patients With Non ST Elevation Acute Coronary Syndrome (NSTE-ACS)[NCT04375319]60 participants (Anticipated)Interventional2019-10-28Recruiting
Anticoagulant Plus Antiplatelet Therapy Following Iliac Vein Stenting[NCT04694248]172 participants (Anticipated)Interventional2021-11-03Recruiting
The Efficacy and Safety of Proton Pump Inhibitor ( in Patients With Moderate Bleeding Risk and Coronary Artery Disease Undergoing Percutaneous Coronary: A Randomised, Open ,Compared With Control[NCT05820048]Phase 4300 participants (Anticipated)Interventional2023-05-01Not yet recruiting
Hunting for the Off-Target Properties of Ticagrelor on Endothelial Function and Other Circulating Biomarkers in Humans[NCT02587260]Phase 454 participants (Actual)Interventional2015-12-17Completed
Evaluation of Antiplatelet Therapy in Lower Limb Endovascular Treatment[NCT00912756]Phase 4200 participants (Anticipated)Interventional2009-03-31Recruiting
Follow-up Management of Peripheral Arterial Intervention With Clopidogrel MIRROR-Study[NCT00163267]Phase 2/Phase 380 participants (Actual)Interventional2005-09-30Completed
Arterial Imaging of Inflammation and Resolution After Endovascular Surgery[NCT03590769]Phase 19 participants (Actual)Interventional2017-06-01Completed
Efficacy of Self-Expanding Nitinol S.M.A.R.T-CONTROL Stent Versus Complete SE Stent For The Atherosclerotic Femoro-Popliteal Arterial Disease : Prospective, Multicenter, Randomized, Controlled Trial (SENS-FP Trial)[NCT01570803]0 participants (Actual)Interventional2013-01-31Withdrawn (stopped due to Study could not be initiated due to lack of research funding from the sponsors.)
The Effect Of Acadesine On Clinically Significant Adverse Cardiovascular and Cerebrovascular Events In High-Risk Subjects Undergoing Coronary Artery Bypass Graft (CABG) Surgery Using Cardiopulmonary Bypass (Protocol No. P05633): RED-CABG Trial (Reduction [NCT00872001]Phase 33,080 participants (Actual)Interventional2009-04-30Terminated
A Multi-center, Randomized, Double-blind and Placebo-controlled Clinical Research of 2200 Cases in Improving Curative Effect of Secondary Prevention for Patients With Ischemic Stroke Through Syndrome Differentiation of TCM[NCT02334969]Phase 42,200 participants (Actual)Interventional2016-04-30Completed
Allogeneic Mesenchymal Stromal Cells for Angiogenesis and Neovascularization in No-option Ischemic Limbs; A Double-blind, Randomized, Placebo-controlled Trial[NCT03042572]Phase 2/Phase 360 participants (Anticipated)Interventional2018-12-31Not yet recruiting
Intra-arterial Infusion of Autologous Bone Marrow Mononuclear Cells in Patients With Chronic Critical Limb Ischemia: a Randomized, Placebo-controlled Clinical Trial[NCT00371371]Phase 1/Phase 2160 participants (Actual)Interventional2006-09-30Completed
A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myoca[NCT01225562]Phase 321,379 participants (Actual)Interventional2010-10-31Completed
Influence of Platelet Reactivity in Peripheral Arterial Disease Patients Undergoing Percutaneous Angioplasty on Mid-term Outcomes[NCT04165629]450 participants (Anticipated)Observational2020-01-01Recruiting
PROlonging Dual Antiplatelet Treatment In Patients With Coronary Artery Disease After Graded Stent-induced Intimal Hyperplasia studY[NCT00611286]Phase 41,700 participants (Anticipated)Interventional2006-12-31Completed
Aspirin Resistance in Obstructive Sleep Apnea Patients (ARISA Trial)[NCT03930875]63 participants (Actual)Observational2017-12-12Completed
Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents[NCT00638794]8,575 participants (Actual)Observational2008-01-31Completed
THE OMEGA-SPM-DOSE and OMEGA-SPM-PAD: Specialized Pro-Resolving Mediators in Patients With Peripheral Artery Disease[NCT02719665]30 participants (Actual)Interventional2016-03-31Completed
Omega EVAR: Use of Fish Oil to Reduce Inflammation During Endovascular Abdominal Aortic Repair.[NCT03208920]2 participants (Actual)Interventional2016-12-31Completed
"Effect of Lipid Modification on Peripheral Arterial Disease After Endovascular Intervention (The ELIMIT Trial)"[NCT00687076]Phase 4102 participants (Actual)Interventional2004-04-30Completed
Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial[NCT00110448]Phase 42,539 participants (Actual)Interventional2002-12-31Completed
Assessment of Exercise Capacity, Physical Activity, Pulmonary Function, Peripheric and Respiratory Muscle Strength, Respiratory Muscle Endurance in Patient With Peripheral Artery Disease[NCT03458754]35 participants (Actual)Observational2018-01-01Completed
Effects of Prolonged Dual Antiplatelet Therapy With Clopidogrel Plus Acetylsalicylic Acid (ASA) After Percutaneous Lower Extremity Revascularization in Patients With Peripheral Arterial Disease[NCT02798913]Phase 3300 participants (Anticipated)Interventional2016-01-31Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

All-cause Mortality

Count of participants and time from randomization to death by all cause were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participants, death by any cause after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

InterventionParticipants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg313
Rivaroxaban 5mg + Aspirin Placebo366
Rivaroxaban Placebo + Aspirin 100mg378

All-cause Mortality in LTOLE Part

Count of participants from COMPASS LTOLE initiation visit to death by all cause were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participants, death by any cause after COMPASS LTOLE initiation visit up until the the last LTOLE part contact date was considered. The mean time in follow-up until that date was 428 days.

InterventionParticipants (Count of Participants)
LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg282

The First Occurrence of MI, Ischemic Stroke, ALI, or Cardiovascular (CV) Death

Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ischemic stroke, ALI, or CV death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

InterventionParticipants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg389
Rivaroxaban 5mg + Aspirin Placebo453
Rivaroxaban Placebo + Aspirin 100mg516

The First Occurrence of Myocardial Infarction (MI), Ischemic Stroke, Acute Limb Ischemia (ALI), or Coronary Heart Disease (CHD) Death

Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CHD death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ALI, or CHD death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

InterventionParticipants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg329
Rivaroxaban 5mg + Aspirin Placebo397
Rivaroxaban Placebo + Aspirin 100mg450

The First Occurrence of the Composite Primary Efficacy Outcome, Myocardial Infarction (MI), Stroke, or Cardiovascular (CV) Death

Count of participants and time from randomization to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

InterventionParticipants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg379
Rivaroxaban 5mg + Aspirin Placebo448
Rivaroxaban Placebo + Aspirin 100mg496

The First Occurrence of the Composite Primary Efficacy Outcome, Myocardial Infarction (MI), Stroke, or Cardiovascular (CV) Death in LTOLE Part

Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after from COMPASS LTOLE initiation visit up until last LTOLE part contact date was considered. The mean time in follow-up was 428 days.

InterventionParticipants (Count of Participants)
LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg353

The First Occurrence of the Primary Safety Outcome Major Bleeding Based on a Modification of the International Society on Thrombosis and Haemostasis (ISTH) Criteria

"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants and time from randomization to the first occurrence of the primary safety outcome major bleeding were evaluated. Hazard ratios were calculated and reported as statistical analysis." (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

InterventionParticipants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg288
Rivaroxaban 5mg + Aspirin Placebo255
Rivaroxaban Placebo + Aspirin 100mg170

The First Occurrence of the Primary Safety Outcome Major Bleeding Based on a Modification of the International Society on Thrombosis and Haemostasis (ISTH) Criteria in LTOLE Part

"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the primary safety outcome major bleeding was evaluated. LTOLE: long-term open-lable extension" (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding from COMPASS LTOLE initiation visit up until 2 days after the last treatment in LTOLE part was considered. The mean time in follow-up was 421 days.

InterventionParticipants (Count of Participants)
LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg138

Number of Mortality (All-cause)

(NCT02504216)
Timeframe: For each participant, the first occurrence of the outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean survival time until ECOD was 1188.48 days

InterventionParticipants (Count of Participants)
Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od321
Rivaroxaban Placebo Bid + Aspirin 100 mg od297

Number of Participants With an Unplanned Index Limb Revascularization for Recurrent Limb Ischemia (Subsequent Index Leg Revascularization That Was Not Planned or Considered as Part of the Initial Treatment Plan at the Time of Randomization)

Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered. (NCT02504216)
Timeframe: For each participant, the first occurrence of the efficacy outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean survival time until ECOD was 1062.48 days.

InterventionParticipants (Count of Participants)
Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od584
Rivaroxaban Placebo Bid + Aspirin 100 mg od655

Number of Participants With Composite of MI, All-cause Stroke, Cardiovascular (CV) Death, Acute Limb Ischemia (ALI), and Major Amputation of a Vascular Etiology

Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered. (NCT02504216)
Timeframe: For each participant, the first occurrence of the composite efficacy outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean survival time until ECOD was 1108.29 days

InterventionParticipants (Count of Participants)
Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od514
Rivaroxaban Placebo Bid + Aspirin 100 mg od588

Number of Participants With Composite of MI, Ischemic Stroke, All-cause Mortality (ACM), ALI, and Major Amputation of a Vascular Etiology

Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered. (NCT02504216)
Timeframe: For each participant, the first occurrence of the composite efficacy outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean survival time until ECOD was 1085.13 days

InterventionParticipants (Count of Participants)
Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od614
Rivaroxaban Placebo Bid + Aspirin 100 mg od679

Number of Participants With Composite of MI, Ischemic Stroke, Coronary Heart Disease (CHD) Death, ALI, and Major Amputation of a Vascular Etiology

Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered. (NCT02504216)
Timeframe: For each participant, the first occurrence of the composite efficacy outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean survival time until ECOD was 1108.79 days.

InterventionParticipants (Count of Participants)
Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od433
Rivaroxaban Placebo Bid + Aspirin 100 mg od528

Number of Participants With Hospitalization for a Coronary or Peripheral Cause (Either Lower Limb) of a Thrombotic Nature

Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered. (NCT02504216)
Timeframe: For each participant, the first occurrence of the efficacy outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean survival time until ECOD was 1154.04 days

InterventionParticipants (Count of Participants)
Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od262
Rivaroxaban Placebo Bid + Aspirin 100 mg od356

Number of Participants With Venous Thromboembolic (VTE) Events

Venous thromboembolic events were reported by investigator only. (NCT02504216)
Timeframe: For each participant, the first occurrence of the outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean survival time until ECOD was 1187.65 days

InterventionParticipants (Count of Participants)
Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od25
Rivaroxaban Placebo Bid + Aspirin 100 mg od41

Primary Efficacy Outcome: Number of Participants With Composite of Myocardial Infarction (MI), Ischemic Stroke, Cardiovascular Death, Acute Limb Ischemia (ALI) and Major Amputation Due to a Vascular Etiology

Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered. (NCT02504216)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean time in follow-up survival time until ECOD that date was 1109.76 days.

InterventionParticipants (Count of Participants)
Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od508
Rivaroxaban Placebo Bid + Aspirin 100 mg od584

Primary Safety Outcome: Number of Participants With TIMI (Thrombolysis in Myocardial Infarction) Major Bleeding

Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered. (NCT02504216)
Timeframe: For each participant, the first occurrence of the primary safety outcome after randomization up until 2 days after permanent stop of study drug (rivaroxaban or rivaroxaban placebo).

InterventionParticipants (Count of Participants)
Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od62
Rivaroxaban Placebo Bid + Aspirin 100 mg od44

Secondary Safety Outcome: Number of Participants With BARC (Bleeding Academic Research Consortium) Type 3b and Above Bleeding Events

Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered (NCT02504216)
Timeframe: For each participant, the first occurrence of the type 3b and above bleeding events according to the BARC classification after randomization up until 2 days after permanent stop of study drug (rivaroxaban or rivaroxaban placebo)

InterventionParticipants (Count of Participants)
Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od93
Rivaroxaban Placebo Bid + Aspirin 100 mg od73

Secondary Safety Outcome: Number of Participants With ISTH (International Society on Thrombosis and Haemostasis) Major Bleeding

Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered. (NCT02504216)
Timeframe: For each participant, the first occurrence of the major bleeding events according to the ISTH classification after randomization up until 2 days after permanent stop of study drug (rivaroxaban or rivaroxaban placebo).

InterventionParticipants (Count of Participants)
Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od140
Rivaroxaban Placebo Bid + Aspirin 100 mg od100

Number of Adjudicated Major Adverse Cardiovascular Events During the Overall Study Period

Number of Adjudicated Major Adverse Cardiovascular Events (MACE) which is a composite of non-fatal myocardial infarction (MI), non-fatal stroke and cardiovascular death (NCT01802775)
Timeframe: within 6 months

InterventionParticipants (Count of Participants)
Clopidogrel1
Edoxaban3

Number of Participants With Amputations

Number of participants with amputations within 6 months (NCT01802775)
Timeframe: within 6 months

InterventionParticipants (Count of Participants)
Clopidogrel3
Edoxaban1

Percentage of Participants With First Re-stenosis / Re-occlusion

Percentage of participants with re-stenosis/re-occlusion during treatment within 6 months - only the first occurrence of re-stenosis / re-occlusion was counted for each participant (NCT01802775)
Timeframe: within 6 months

Interventionpercentage of participants (Number)
Clopidogrel34.7
Edoxaban30.9

Safety Assessments

"Number of participants with serious adverse events (SAEs) within 6 months~Note: Based on changes to the database structure, clinically significant changes in physical or laboratory parameters are recorded as adverse events (AEs). Details of non-serious adverse events are reported at the 5% reporting threshold in the AE module, as is all-cause mortality." (NCT01802775)
Timeframe: within 6 months

InterventionParticipants (Count of Participants)
Clopidogrel30
Edoxaban31

Percentage of Participants With Clinically Relevant Bleeding During Treatment

Percentage of participants with clinically relevant bleeding, defined as major bleeding or clinical relevant non-major bleeding, in the on-treatment period based on International Society of Thrombosis and Haemostasis (ISTH) (NCT01802775)
Timeframe: at 3 months

,
Interventionpercentage of participants (Number)
Including Access Site Bleeding (IASB)Excluding Access Site Bleed (EASB)
Clopidogrel86
Edoxaban116

Percentage of Participants With Major, Clinically Relevant Non-major (CRNM), and Minor Bleeding During Treatment

The percentage of participants with major, clinically relevant non-major, and minor bleeding occurring during treatment, within 3 months (NCT01802775)
Timeframe: within 3 months

,
Interventionpercentage of participants (Number)
IASB : Major BleedingIASB: CRNM BleedingIASB: Minor BleedingEASB : Major BleedingEASB : CRNM BleedingEASB : Minor Bleeding
Clopidogrel5420.84317.8
Edoxaban110201519

Change From Baseline in Log Transformed Claudication Onset Time (COT) at Week 26 or Early Termination (ET)

(NCT02227368)
Timeframe: 26 Weeks

Interventionlog(Second) (Mean)
Ticagrelor0.6
Aspirin0.5

Change From Baseline in Log Transformed Peak Walking Time (PWT) at Week 26 or Early Termination (ET)

(NCT02227368)
Timeframe: 26 Weeks

Interventionlog(Second) (Mean)
Ticagrelor0.0
Aspirin0.1

Incidence of All-cause Death, Non-fatal Stroke, and Need for Mechanical Support for Severe Left Ventricular Dysfunction (SLVD) (Intent-to-Treat Population)

Incidence of all-cause death, non-fatal stroke, or need for mechanical support for SLVD (any component and composite) through post-operative Day 28 during and following CABG and administration of acadesine or placebo. Components defined as follows: All-cause death: Death from any cause, Non-fatal Stoke: occurrence of a stoke that was confirmed and adjudicated by Clinical Endpoints Committee that did not result in death, and Mechanical Support for SLVD: New use of any mechanical support for ≥1 hour for treatment of low cardiac output. (NCT00872001)
Timeframe: Up to Post-Operative Day 28

,
InterventionPercentage of Participants (Number)
Composite of All EventsAll-Cause DeathNon-Fatal StrokeNeed for Mechanical Support for SLVD
Acadesine4.91.91.72.2
Placebo4.91.71.72.3

Incidence of Cardiovascular Death, Non-fatal Stroke, and Need for Mechanical Support for SLVD (Intent-to-Treat Population)

Incidence of cardiovascular death, non-fatal stroke, and need for mechanical support for SLVD (any component and composite) through post-operative Day 28 during and following CABG and administration of acadesine or placebo. Components defined as follows: Cardiovascular death: Death due to cardiovascular causes, Non-fatal Stroke: occurrence of a stroke that was confirmed and adjudicated by Clinical Endpoints Committee that did not result in death, and Mechanical Support for SLVD: New use of any mechanical support for ≥1 hour for treatment of low cardiac output. (NCT00872001)
Timeframe: Up to Post-Operative Day 28

,
InterventionPercentage of Participants (Number)
Composite of All EventsCardiovascular DeathNon-Fatal StrokeNeed for Mechanical Support for SLVD
Acadesine4.81.71.72.2
Placebo (Normal Saline)4.71.61.72.3

Kaplan-Meier Estimate of the Percentage of Patients Who Died From Any Cause Within 3 Years From Randomization

Participants with death from any cause. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent or the last time point the particapant was known to be alive. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who died from any cause within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months

InterventionPercentage of Patients (Number)
Ticagrelor 90 mg5.1
Ticagrelor 60 mg4.7
Placebo5.2

Kaplan-Meier Estimate of the Percentage of Patients Who Experienced a TIMI Major Bleeding Within 3 Years From First Dose of Study Drug Units: Percentage of Patients

A Thrombolysis in Myocardial Infarction (TIMI) study group major bleeding is defined as any fatal bleeding (leading directly to death within 7 days), any intrcranial bleeding or any clinically overt signs of haemorrhage associated with a drop in Haemoglobin of >= 5g/dL. Events were adjudicated by a clinical events committee. Censoring ocurrs at 7 days following last dose of study drug. The Kaplan-Meier estimate reports the percentage of patients who experienced a TIMI Major bleeding within 3 years from first dose of study drug (NCT01225562)
Timeframe: First dosing up to 48 months

InterventionPercentage of Patients (Number)
Ticagrelor 90 mg2.6
Ticagrelor 60 mg2.3
Placebo1.1

Kaplan-Meier Estimate of the Percentage of Patients Who Experienced Cardiovascular Death (CV Death) Within 3 Years From Randomization

Participants with CV death. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent, non-CV death or at the last time point of complete clinical event assessment. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who experienced CV Death within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months

InterventionPercentage of Patients (Number)
Ticagrelor 90 mg2.9
Ticagrelor 60 mg2.9
Placebo3.4

Kaplan-Meier Estimate of the Percentage of Patients Who Experienced Cardiovascular Death (CV Death), Myocardial Infarction (MI) or Stroke Within 3 Years From Randomization

Participants with CV death, MI or Stroke. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent, non-CV death or at the last time point of complete clinical event assessment. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who experienced CV Death, MI or stroke within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months

InterventionPercentage of Patients (Number)
Ticagrelor 90 mg7.8
Ticagrelor 60 mg7.8
Placebo9.0

Change in Total Cholesterol (mg/dl) From Baseline to Month 12

Lipids: Total cholesterol (mg/dl); Lipid Data at 12-Months (change from baseline) [mg/dl]. (NCT00687076)
Timeframe: Measured at baseline and 12 months

Interventionmg/dl (Median)
Triple Therapy-30.0
Mono Therapy-7.5

Effect of Intensive Lipid Modification Medication Therapy on Progression of Atherosclerosis and Restenosis of Femoral Arteries Measured Using High Resolution Magnetic Resonance Imaging (MRI) to Examine the Femoral Artery for Progression of Atherosclerosis

"The primary outcome variable was the change in superficial femoral artery (SFA) wall volume over 24-months, as determined by MRI. The 24-month changes in SFA lumen and SFA total vessel volumes were also analyzed.~Analysis details: A total of 102 patients were randomized. 87 patients completed baseline MRI. Between randomization and the baseline visit, 1 patient withdrew from the study, 8 patients opted out from baseline imaging, and 6 additional patients declined blood collection at baseline. The multilevel models (primary endpoint) used all available imaging data (n=91), including patients who only completed baseline imaging (n=20) or completed at least 2 imaging visits other than baseline (n=4)." (NCT00687076)
Timeframe: Measured at baseline and 24 Months

Interventionmm^3, at 24-months (Mean)
Triple Therapy58.1
Mono Therapy60.5

Reviews

49 reviews available for aspirin and Peripheral Arterial Diseases

ArticleYear
Efficacy and Safety of Rivaroxaban Compared with Other Therapies Used in Patients with Peripheral Artery Disease Undergoing Peripheral Revascularization: A Systematic Literature Review and Network Meta-Analysis.
    Cardiovascular therapeutics, 2021, Volume: 2021

    Topics: Adult; Aspirin; Humans; Network Meta-Analysis; Peripheral Arterial Disease; Platelet Aggregation Inh

2021
Review new concepts in pharmacotherapy for peripheral arterial disease.
    Current opinion in cardiology, 2021, 11-01, Volume: 36, Issue:6

    Topics: Aspirin; Drug Therapy, Combination; Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibi

2021
Combination anticoagulant or P2Y12 inhibitor with low-dose aspirin versus low-dose aspirin alone in patients at risk or with documented coronary and/or peripheral artery disease.
    Current medical research and opinion, 2022, Volume: 38, Issue:1

    Topics: Adult; Anticoagulants; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Factor Xa Inhibi

2022
Protease-Activated Receptor Antagonist for Reducing Cardiovascular Events - A Review on Vorapaxar.
    Current problems in cardiology, 2023, Volume: 48, Issue:3

    Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Myocardial Infarction; Peripheral Arterial Di

2023
Update on the pathophysiology and medical treatment of peripheral artery disease.
    Nature reviews. Cardiology, 2022, Volume: 19, Issue:7

    Topics: Aspirin; Humans; Pain; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Quality of Life

2022
Antithrombotic Therapy in Peripheral Artery Disease: Risk Stratification and Clinical Decision Making.
    The Canadian journal of cardiology, 2022, Volume: 38, Issue:5

    Topics: Aspirin; Canada; Clinical Decision-Making; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhag

2022
A comprehensive review on antithrombotic therapy for peripheral artery disease.
    Seminars in vascular surgery, 2022, Volume: 35, Issue:2

    Topics: Anticoagulants; Aspirin; Fibrinolytic Agents; Humans; Peripheral Arterial Disease; Platelet Aggregat

2022
Antithrombotic Therapy for Symptomatic Peripheral Arterial Disease: A Systematic Review and Network Meta-Analysis.
    Drugs, 2022, Volume: 82, Issue:12

    Topics: Aspirin; Clopidogrel; Fibrinolytic Agents; Hemorrhage; Humans; Network Meta-Analysis; Peripheral Art

2022
Early identification and treatment for peripheral arterial disease in patients with ischemic cerebrovascular disease.
    European journal of medical research, 2023, Feb-23, Volume: 28, Issue:1

    Topics: Aspirin; Atherosclerosis; Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Stro

2023
Who may benefit from low-dose rivaroxaban plus aspirin? Practical implications for outpatients with cardiovascular disease.
    Polish archives of internal medicine, 2023, 10-26, Volume: 133, Issue:10

    Topics: Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Ischemia;

2023
Rivaroxaban and Aspirin in Peripheral Vascular Disease: a Review of Implementation Strategies and Management of Common Clinical Scenarios.
    Current cardiology reports, 2019, 08-30, Volume: 21, Issue:10

    Topics: Anticoagulants; Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; Factor Xa Inhibitors; F

2019
Monotherapy with a P2Y
    Lancet (London, England), 2020, 05-09, Volume: 395, Issue:10235

    Topics: Aged; Aspirin; Atherosclerosis; Cerebrovascular Disorders; Clopidogrel; Coronary Disease; Female; He

2020
Dual Pathway Inhibition for Vascular Protection in Patients with Atherosclerotic Disease: Rationale and Review of the Evidence.
    Thrombosis and haemostasis, 2020, Volume: 120, Issue:8

    Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atherosclerosis; Dose-Response Relationship, Drug;

2020
[Do the patients with peripheral atherosclerosis need to a medical therapy before the revascularization?]
    Terapevticheskii arkhiv, 2019, Dec-15, Volume: 91, Issue:12

    Topics: Aspirin; Atherosclerosis; Drug Therapy, Combination; Humans; Peripheral Arterial Disease; Rivaroxaba

2019
Aspirin and low-dose rivaroxaban - the dual pathway concept in patients with stable atherosclerotic disease: a comprehensive review.
    Expert review of cardiovascular therapy, 2020, Volume: 18, Issue:9

    Topics: Aspirin; Atherosclerosis; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Humans; Perip

2020
Efficacy and Safety of Antiplatelet Therapies in Symptomatic Peripheral Artery Disease: A Systematic Review and Network Meta-Analysis.
    Current vascular pharmacology, 2021, Volume: 19, Issue:5

    Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Network Meta-Analysis; Peripheral Arterial

2021
The efficacy and safety of direct oral anticoagulants plus aspirin in symptomatic lower extremity peripheral arterial disease: a systematic review and meta-analysis of randomized controlled trials.
    Journal of thrombosis and thrombolysis, 2021, Volume: 52, Issue:3

    Topics: Anticoagulants; Aspirin; Factor Xa Inhibitors; Hemorrhage; Humans; Ischemia; Lower Extremity; Periph

2021
Clinical considerations after endovascular therapy of peripheral artery disease.
    Expert review of cardiovascular therapy, 2021, Volume: 19, Issue:5

    Topics: Antihypertensive Agents; Aspirin; Endovascular Procedures; Humans; Hydroxymethylglutaryl-CoA Reducta

2021
Contemporary Medical Management of Peripheral Artery Disease.
    Circulation research, 2021, 06-11, Volume: 128, Issue:12

    Topics: Aspirin; Atherosclerosis; Cardiovascular Diseases; Chronic Limb-Threatening Ischemia; Exercise; Fibr

2021
Antithrombotic Therapy in Patients with Peripheral Artery Disease: A Focused Review on Oral Anticoagulation.
    International journal of molecular sciences, 2021, Jul-01, Volume: 22, Issue:13

    Topics: Anticoagulants; Aspirin; Blood Coagulation; Drug Therapy, Combination; Factor Xa Inhibitors; Fibrino

2021
Network Meta-analysis of the Benefit of Aspirin with Rivaroxaban vs. Clopidogrel for Patients with Stable Symptomatic Lower Extremity Arterial Disease.
    European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2021, Volume: 62, Issue:4

    Topics: Aged; Aspirin; Clopidogrel; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Hemorrhage; Humans; L

2021
Pharmacological secondary prevention in patients with mesenterial artery atherosclerosis and arterial embolism.
    Best practice & research. Clinical gastroenterology, 2017, Volume: 31, Issue:1

    Topics: Anticoagulants; Aspirin; Atherosclerosis; Embolism; Humans; Peripheral Arterial Disease; Secondary P

2017
Review of aspirin and clopidogrel resistance in peripheral arterial disease.
    Journal of vascular surgery, 2017, Volume: 66, Issue:5

    Topics: Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Resistance; Genotype; Humans; Peripheral Arteri

2017
Advances in the Treatment of Stable Coronary Artery Disease and Peripheral Artery Disease.
    Critical pathways in cardiology, 2018, Volume: 17, Issue:2

    Topics: Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Disease; DNA; Drug Therapy, Combination; Facto

2018
A systematic review of the efficacy of aspirin monotherapy versus other antiplatelet therapy regimens in peripheral arterial disease.
    Journal of vascular surgery, 2018, Volume: 67, Issue:6

    Topics: Aspirin; Endovascular Procedures; Fibrinolytic Agents; Humans; Peripheral Arterial Disease; Platelet

2018
Screening for Peripheral Artery Disease Using the Ankle-Brachial Index: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    JAMA, 2018, 07-10, Volume: 320, Issue:2

    Topics: Ankle Brachial Index; Aspirin; Asymptomatic Diseases; Early Diagnosis; Exercise Therapy; Fibrinolyti

2018
Dual vs single antiplatelet therapy in patients with lower extremity peripheral artery disease - A meta-analysis.
    International journal of cardiology, 2018, Oct-15, Volume: 269

    Topics: Aspirin; Drug Therapy, Combination; Humans; Lower Extremity; Peripheral Arterial Disease; Platelet A

2018
[Anti-Thrombotic Treatment of Patients with Peripheral Artery Disease (PAD)].
    Deutsche medizinische Wochenschrift (1946), 2018, Volume: 143, Issue:15

    Topics: Administration, Oral; Anticoagulants; Aspirin; Blood Vessel Prosthesis Implantation; Clopidogrel; Dr

2018
Novel Oral Anticoagulants in Peripheral Artery Disease: Current Evidence.
    Current pharmaceutical design, 2018, Volume: 24, Issue:38

    Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Hemorrhage; Humans;

2018
Rivaroxaban versus Clopidogrel for Peripheral Artery Disease: A Clinico-Economic Approach of the COMPASS Trial.
    Current pharmaceutical design, 2018, Volume: 24, Issue:38

    Topics: Anticoagulants; Aspirin; Cardiovascular Diseases; Clopidogrel; Cost-Benefit Analysis; Drug Therapy,

2018
Antithrombotic Agents.
    Circulation research, 2019, Volume: 124, Issue:3

    Topics: Administration, Oral; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Clinical Trials a

2019
Combination Antiplatelet and Oral Anticoagulant Therapy in Patients With Coronary and Peripheral Artery Disease.
    Circulation, 2019, 04-30, Volume: 139, Issue:18

    Topics: Administration, Oral; Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Disease; Humans; Percuta

2019
How can the results of the COMPASS trial benefit patients with coronary or peripheral artery disease in Poland?
    Kardiologia polska, 2019, Aug-23, Volume: 77, Issue:7-8

    Topics: Aged; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Hum

2019
Is aspirin still the drug of choice for management of patients with peripheral arterial disease?
    VASA. Zeitschrift fur Gefasskrankheiten, 2013, Volume: 42, Issue:2

    Topics: Aspirin; Cardiovascular Diseases; Disease Progression; Fibrinolytic Agents; Humans; Peripheral Arter

2013
High on-treatment platelet reactivity in peripheral endovascular procedures.
    Cardiovascular and interventional radiology, 2014, Volume: 37, Issue:3

    Topics: Aspirin; Atherosclerosis; Blood Platelets; Clopidogrel; Endovascular Procedures; Humans; Peripheral

2014
Management of patients after endovascular interventions for peripheral artery disease.
    Circulation, 2013, Aug-13, Volume: 128, Issue:7

    Topics: Aftercare; Angioplasty, Balloon; Ankle Brachial Index; Aspirin; Cilostazol; Clinical Trials as Topic

2013
The ankle-brachial index for peripheral artery disease screening and cardiovascular disease prediction among asymptomatic adults: a systematic evidence review for the U.S. Preventive Services Task Force.
    Annals of internal medicine, 2013, Sep-03, Volume: 159, Issue:5

    Topics: Adult; Ankle Brachial Index; Aspirin; Asymptomatic Diseases; Cardiovascular Diseases; Fibrinolytic A

2013
Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease.
    Annals of medicine, 2014, Volume: 46, Issue:7

    Topics: Adenosine; Aspirin; Asymptomatic Diseases; Cilostazol; Clopidogrel; Fibrinolytic Agents; Humans; Int

2014
Antiplatelet therapy for peripheral arterial disease and critical limb ischemia: guidelines abound, but where are the data?
    Journal of cardiovascular pharmacology and therapeutics, 2015, Volume: 20, Issue:2

    Topics: Aspirin; Cilostazol; Dipyridamole; Endovascular Procedures; Extremities; Humans; Ischemia; Periphera

2015
Comparative effectiveness review of antiplatelet agents in peripheral artery disease.
    Journal of the American Heart Association, 2014, Dec-04, Volume: 3, Issue:6

    Topics: Aspirin; Clopidogrel; Comparative Effectiveness Research; Drug Therapy, Combination; Humans; Patient

2014
The year in cardiology 2014: peripheral circulation.
    European heart journal, 2015, Mar-07, Volume: 36, Issue:10

    Topics: Anticoagulants; Aortic Aneurysm, Abdominal; Aspirin; Biomarkers; Carotid Artery Diseases; Endovascul

2015
A Meta-Analysis of Randomized Controlled Trials on Antiplatelet Agents Versus Placebo/Control for Treating Peripheral Artery Disease.
    Medicine, 2015, Volume: 94, Issue:31

    Topics: Aspirin; Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Randomized Controlled

2015
Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2015, Oct-01, Volume: 72, Issue:19

    Topics: Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Half-Life; Hemorrhage; Humans; L

2015
Antithrombotic Therapy After Peripheral Vascular Intervention.
    Current cardiology reports, 2016, Volume: 18, Issue:3

    Topics: Angioplasty, Balloon; Aspirin; Atherectomy; Fibrinolytic Agents; Humans; Peripheral Arterial Disease

2016
Vorapaxar and diplopia: Possible off-target PAR-receptor mismodulation.
    Thrombosis and haemostasis, 2016, 05-02, Volume: 115, Issue:5

    Topics: Animals; Aspirin; Clopidogrel; Diplopia; Drug Approval; Eye; Humans; Lactones; Peripheral Arterial D

2016
[The basis of platelets: platelets and atherothrombosis: an understanding of the lack of efficacy of aspirin in peripheral arterial disease (PAD) and diabetic patients].
    Drugs, 2010, Nov-01, Volume: 70 Suppl 1

    Topics: Abbreviations as Topic; Aspirin; Atherosclerosis; Blood Platelets; Clinical Trials as Topic; Diabete

2010
Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis.
    Health technology assessment (Winchester, England), 2011, Volume: 15, Issue:31

    Topics: Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Clopidogrel; Cost-Benefit Analysis; Delayed-Ac

2011
Antiplatelet therapy in peripheral artery disease.
    Handbook of experimental pharmacology, 2012, Issue:210

    Topics: Ankle Brachial Index; Arachidonic Acid; Aspirin; Humans; Peripheral Arterial Disease; Platelet Aggre

2012
[Antithrombotic therapy after peripheral vascular treatment: what is evidence-based?].
    Zentralblatt fur Chirurgie, 2012, Volume: 137, Issue:5

    Topics: Aortic Diseases; Aspirin; Blood Vessel Prosthesis Implantation; Clopidogrel; Dose-Response Relations

2012

Trials

61 trials available for aspirin and Peripheral Arterial Diseases

ArticleYear
Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone.
    Journal of thrombosis and haemostasis : JTH, 2022, Volume: 20, Issue:5

    Topics: Anticoagulants; Arteries; Aspirin; Endovascular Procedures; Humans; Lower Extremity; Peripheral Arte

2022
Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial.
    European heart journal. Cardiovascular pharmacotherapy, 2022, 12-02, Volume: 8, Issue:8

    Topics: Aspirin; Drug Therapy, Combination; Humans; Infant; Myocardial Infarction; Peripheral Arterial Disea

2022
Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: The XATOA Registry.
    European heart journal. Cardiovascular pharmacotherapy, 2022, 12-02, Volume: 8, Issue:8

    Topics: Aged; Aspirin; Coronary Artery Disease; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Peri

2022
Sex-Based Differences in Outcomes Following Peripheral Artery Revascularization: Insights From VOYAGER PAD.
    Journal of the American Heart Association, 2022, 06-21, Volume: 11, Issue:12

    Topics: Arteries; Aspirin; Endovascular Procedures; Female; Hemorrhage; Humans; Lower Extremity; Male; Perip

2022
Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Revascularization.
    JAMA network open, 2022, 06-01, Volume: 5, Issue:6

    Topics: Aged; Aspirin; Clopidogrel; Cohort Studies; Female; Humans; Lower Extremity; Male; Peripheral Arteri

2022
Rivaroxaban and aspirin vs. aspirin alone in Asian compared with non-Asian patients with chronic coronary artery disease or peripheral arterial disease: the COMPASS trial.
    European heart journal, 2022, 10-07, Volume: 43, Issue:37

    Topics: Asian People; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Hemorrhage; Humans; Perip

2022
CYP2C19 genotype-guided antithrombotic treatment versus conventional clopidogrel therapy in peripheral arterial disease: study design of a randomized controlled trial (GENPAD).
    American heart journal, 2022, Volume: 254

    Topics: Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Humans; Myocardial Infarction; Peripheral

2022
The cost-effectiveness of rivaroxaban with or without aspirin in the COMPASS trial.
    European heart journal. Quality of care & clinical outcomes, 2023, 08-07, Volume: 9, Issue:5

    Topics: Aspirin; Cost-Benefit Analysis; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Peripheral

2023
Efficacy and safety of rivaroxaban versus placebo after lower extremity bypass surgery: A post hoc analysis of a "CASPAR like" outcome from VOYAGER PAD.
    Clinical cardiology, 2022, Volume: 45, Issue:12

    Topics: Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Ischemia; Lower Extremity; Myocardial Infarc

2022
Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits.
    Journal of vascular surgery, 2023, Volume: 77, Issue:4

    Topics: Aspirin; Hemorrhage; Humans; Ischemia; Lower Extremity; Myocardial Infarction; Peripheral Arterial D

2023
Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits.
    Journal of vascular surgery, 2023, Volume: 77, Issue:4

    Topics: Aspirin; Hemorrhage; Humans; Ischemia; Lower Extremity; Myocardial Infarction; Peripheral Arterial D

2023
Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits.
    Journal of vascular surgery, 2023, Volume: 77, Issue:4

    Topics: Aspirin; Hemorrhage; Humans; Ischemia; Lower Extremity; Myocardial Infarction; Peripheral Arterial D

2023
Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits.
    Journal of vascular surgery, 2023, Volume: 77, Issue:4

    Topics: Aspirin; Hemorrhage; Humans; Ischemia; Lower Extremity; Myocardial Infarction; Peripheral Arterial D

2023
Total events and net clinical benefit of rivaroxaban and aspirin in patients with chronic coronary or peripheral artery disease: The COMPASS trial.
    American heart journal, 2023, Volume: 258

    Topics: Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Human

2023
A multicenter, randomized, open-labelled, non-inferiority trial of sustained-release sarpogrelate versus clopidogrel after femoropopliteal artery intervention.
    Scientific reports, 2023, 02-13, Volume: 13, Issue:1

    Topics: Aspirin; Clopidogrel; Delayed-Action Preparations; Drug Therapy, Combination; Femoral Artery; Humans

2023
The predictive value of interarm systolic blood pressure differences in patients with vascular disease: Sub-analysis of the COMPASS trial.
    Atherosclerosis, 2023, Volume: 372

    Topics: Aspirin; Blood Pressure; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Peripheral Arteria

2023
Outcomes among patients with peripheral artery disease in the Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness (ADAPTABLE) study.
    Vascular medicine (London, England), 2023, Volume: 28, Issue:2

    Topics: Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Patient-Centered Care; Peripheral

2023
Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis.
    Circulation, 2019, 10-29, Volume: 140, Issue:18

    Topics: Aged; Aspirin; Atherosclerosis; Coronary Artery Disease; Drug Therapy, Combination; Female; Gastroin

2019
Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis.
    Circulation, 2019, 10-29, Volume: 140, Issue:18

    Topics: Aged; Aspirin; Atherosclerosis; Coronary Artery Disease; Drug Therapy, Combination; Female; Gastroin

2019
Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis.
    Circulation, 2019, 10-29, Volume: 140, Issue:18

    Topics: Aged; Aspirin; Atherosclerosis; Coronary Artery Disease; Drug Therapy, Combination; Female; Gastroin

2019
Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis.
    Circulation, 2019, 10-29, Volume: 140, Issue:18

    Topics: Aged; Aspirin; Atherosclerosis; Coronary Artery Disease; Drug Therapy, Combination; Female; Gastroin

2019
Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin.
    Journal of the American College of Cardiology, 2019, 09-24, Volume: 74, Issue:12

    Topics: Aged; Aspirin; Coronary Artery Disease; Drug Combinations; Factor Xa Inhibitors; Female; Hemorrhage;

2019
Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial.
    European journal of preventive cardiology, 2020, Volume: 27, Issue:3

    Topics: Aged; Anticoagulants; Aspirin; Chronic Disease; Coronary Artery Disease; Double-Blind Method; Drug T

2020
Xarelto plus Acetylsalicylic acid: Treatment patterns and Outcomes in patients with Atherosclerosis (XATOA): Rationale and design of a prospective registry study to assess rivaroxaban 2.5 mg twice daily plus aspirin for prevention of atherothrombotic even
    American heart journal, 2020, Volume: 222

    Topics: Aspirin; Atherosclerosis; Coronary Thrombosis; Dose-Response Relationship, Drug; Drug Administration

2020
Synergistic influence of rivaroxaban on inflammation and coagulation biomarkers in patients with coronary artery disease and peripheral artery disease on aspirin therapy.
    Future cardiology, 2020, Volume: 16, Issue:2

    Topics: Aged; Aspirin; Biomarkers; Blood Coagulation; Coronary Artery Disease; Drug Therapy, Combination; Fa

2020
Rivaroxaban in Peripheral Artery Disease after Revascularization.
    The New England journal of medicine, 2020, 05-21, Volume: 382, Issue:21

    Topics: Aged; Aspirin; Cardiovascular Diseases; Combined Modality Therapy; Double-Blind Method; Drug Therapy

2020
Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease.
    Cardiovascular research, 2021, 02-22, Volume: 117, Issue:3

    Topics: Aged; Aged, 80 and over; Aspirin; Comorbidity; Coronary Artery Disease; Double-Blind Method; Drug Ad

2021
Optimal duration of dual antiplatelet therapy following PTA of the superficial femoral artery: the DAPT-SFA protocol.
    The Journal of cardiovascular surgery, 2020, Volume: 61, Issue:3

    Topics: Angioplasty; Aspirin; Clopidogrel; Drug Administration Schedule; Femoral Artery; Hemorrhage; Humans;

2020
Intracranial and systemic atherosclerosis in the NAVIGATE ESUS trial: Recurrent stroke risk and response to antithrombotic therapy.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2020, Volume: 29, Issue:8

    Topics: Aged; Aspirin; Double-Blind Method; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Humans; Intra

2020
Rationale and design for the study Apixaban versus ClopidoGRel on a background of aspirin in patient undergoing InfraPoPliteal angioplasty for critical limb ischemia: AGRIPPA trial.
    American heart journal, 2020, Volume: 227

    Topics: Angioplasty; Aspirin; Clopidogrel; Critical Illness; Factor Xa Inhibitors; Humans; Ischemia; Leg; Mu

2020
Eligibility for Low-Dose Rivaroxaban Based on the COMPASS Trial: Insights from the Veterans Affairs Healthcare System.
    Cardiovascular drugs and therapy, 2021, Volume: 35, Issue:3

    Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Budgets; Cardiovascular Diseases; Ci

2021
Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Subanalysis of the COMPASS Randomized Clinical Trial.
    JAMA cardiology, 2021, 01-01, Volume: 6, Issue:1

    Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus; Double

2021
Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and Safety.
    Circulation, 2020, 12-08, Volume: 142, Issue:23

    Topics: Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Factor Xa Inhibitors; Fe

2020
Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease.
    Heart (British Cardiac Society), 2021, Volume: 107, Issue:14

    Topics: Aged; Aspirin; Coronary Disease; Drug Monitoring; Drug Substitution; Drug Therapy, Combination; Dura

2021
Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease.
    Journal of the American College of Cardiology, 2021, 07-06, Volume: 78, Issue:1

    Topics: Aged; Aspirin; Coronary Artery Disease; Diabetes Mellitus; Drug Therapy, Combination; Factor Xa Inhi

2021
Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial.
    Circulation, 2021, 10-05, Volume: 144, Issue:14

    Topics: Aged; Aspirin; Female; Humans; Male; Middle Aged; Peripheral Arterial Disease; Rivaroxaban

2021
Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial.
    European heart journal, 2021, 10-14, Volume: 42, Issue:39

    Topics: Aged; Aspirin; Brain Ischemia; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Peripheral A

2021
Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study.
    JACC. Cardiovascular interventions, 2017, 05-08, Volume: 10, Issue:9

    Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Double-Blind Method; Drug

2017
SAFE (Sarpogrelate Anplone in Femoro-popliteal artery intervention Efficacy) study: study protocol for a randomized controlled trial.
    Trials, 2017, Sep-22, Volume: 18, Issue:1

    Topics: Amputation, Surgical; Aspirin; Clinical Protocols; Clopidogrel; Computed Tomography Angiography; Con

2017
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
    Lancet (London, England), 2018, 01-20, Volume: 391, Issue:10117

    Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response

2018
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
    Lancet (London, England), 2018, 01-20, Volume: 391, Issue:10117

    Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response

2018
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
    Lancet (London, England), 2018, 01-20, Volume: 391, Issue:10117

    Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response

2018
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
    Lancet (London, England), 2018, 01-20, Volume: 391, Issue:10117

    Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response

2018
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
    Lancet (London, England), 2018, 01-20, Volume: 391, Issue:10117

    Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response

2018
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
    Lancet (London, England), 2018, 01-20, Volume: 391, Issue:10117

    Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response

2018
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
    Lancet (London, England), 2018, 01-20, Volume: 391, Issue:10117

    Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response

2018
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
    Lancet (London, England), 2018, 01-20, Volume: 391, Issue:10117

    Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response

2018
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
    Lancet (London, England), 2018, 01-20, Volume: 391, Issue:10117

    Topics: Aged; Amputation, Surgical; Aspirin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response

2018
Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease: The COMPASS Trial.
    Journal of the American College of Cardiology, 2018, 05-22, Volume: 71, Issue:20

    Topics: Aged; Aspirin; Double-Blind Method; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Follow-

2018
Edoxaban Plus Aspirin vs Dual Antiplatelet Therapy in Endovascular Treatment of Patients With Peripheral Artery Disease: Results of the ePAD Trial.
    Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists, 2018, Volume: 25, Issue:2

    Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Endovascular Procedures; Europe; Factor Xa In

2018
Ticagrelor in Peripheral Artery Disease Endovascular Revascularization (TI-PAD): Challenges in clinical trial execution.
    Vascular medicine (London, England), 2018, Volume: 23, Issue:6

    Topics: Aged; Aspirin; Double-Blind Method; Early Termination of Clinical Trials; Endovascular Procedures; F

2018
Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD).
    American heart journal, 2018, Volume: 199

    Topics: Aspirin; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Endovascu

2018
Ticagrelor and the Prevention of Microvascular Complications in Diabetes Patients with Lower Extremity Arterial Disease; Rationale and Design of the Hema-Kinesis Trial.
    Cardiovascular drugs and therapy, 2018, Volume: 32, Issue:5

    Topics: Aspirin; Blood Flow Velocity; Blood Viscosity; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabet

2018
Stroke Outcomes in the COMPASS Trial.
    Circulation, 2019, 02-26, Volume: 139, Issue:9

    Topics: Aged; Aged, 80 and over; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Female; Follow

2019
Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease.
    Circulation research, 2019, Volume: 124, Issue:3

    Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cardiovascular Diseases; Chronic Disease; Corona

2019
Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS Trial.
    Journal of the American College of Cardiology, 2019, 05-14, Volume: 73, Issue:18

    Topics: Aged; Aspirin; Coronary Artery Disease; Correlation of Data; Double-Blind Method; Drug Therapy, Comb

2019
Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin.
    Gastroenterology, 2019, Volume: 157, Issue:3

    Topics: Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; Enterocol

2019
Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin.
    Gastroenterology, 2019, Volume: 157, Issue:3

    Topics: Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; Enterocol

2019
Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin.
    Gastroenterology, 2019, Volume: 157, Issue:3

    Topics: Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; Enterocol

2019
Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin.
    Gastroenterology, 2019, Volume: 157, Issue:3

    Topics: Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; Enterocol

2019
Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease.
    Circulation, 2019, 08-13, Volume: 140, Issue:7

    Topics: Aged; Aspirin; Chronic Disease; Coronary Artery Disease; Double-Blind Method; Drug Therapy, Combinat

2019
Effectiveness of antiplatelet therapy in atherosclerotic disease: comparing the ASA low-response prevalence in CVD, CAD and PAD.
    Journal of thrombosis and thrombolysis, 2014, Volume: 37, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Coronary Artery Disease; Female; Humans; Male; Middle Aged;

2014
Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study.
    Circulation, 2013, Jun-11, Volume: 127, Issue:23

    Topics: Aged; Aged, 80 and over; Alloys; Angioplasty; Aspirin; Cardiovascular Diseases; Cilostazol; Constric

2013
Twelve-month results of a randomized trial comparing mono with dual antiplatelet therapy in endovascularly treated patients with peripheral artery disease.
    Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists, 2013, Volume: 20, Issue:5

    Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Aspirin; Clopidogrel; Double-Blind Method; Drug Thera

2013
Efficacy of two different self-expanding nitinol stents for atherosclerotic femoropopliteal arterial disease (SENS-FP trial): study protocol for a randomized controlled trial.
    Trials, 2014, Sep-10, Volume: 15

    Topics: Alloys; Angioplasty, Balloon; Aspirin; Cilostazol; Clinical Protocols; Clopidogrel; Drug Therapy, Co

2014
Predictors of contemporary coronary artery bypass grafting outcomes.
    The Journal of thoracic and cardiovascular surgery, 2014, Volume: 148, Issue:6

    Topics: Age Factors; Aminoimidazole Carboxamide; Aspirin; Cardiopulmonary Bypass; Cardiovascular Agents; Chi

2014
The efficacy and safety of cilostazol in ischemic stroke patients with peripheral arterial disease (SPAD): protocol of a randomized, double-blind, placebo-controlled multicenter trial.
    International journal of stroke : official journal of the International Stroke Society, 2015, Volume: 10, Issue:1

    Topics: Aspirin; Cilostazol; Double-Blind Method; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hu

2015
A review of antithrombotic therapy and the rationale and design of the randomized edoxaban in patients with peripheral artery disease (ePAD) trial adding edoxaban or clopidogrel to aspirin after femoropopliteal endovascular intervention.
    Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists, 2015, Volume: 22, Issue:2

    Topics: Aged; Angioplasty; Aspirin; Clopidogrel; Drug Therapy, Combination; Europe; Factor Xa Inhibitors; Fe

2015
Baseline Platelet Activation and Reactivity in Patients with Critical Limb Ischemia.
    PloS one, 2015, Volume: 10, Issue:7

    Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Case-Control Studies; Collagen; Female; Fibrinoge

2015
Baseline Platelet Activation and Reactivity in Patients with Critical Limb Ischemia.
    PloS one, 2015, Volume: 10, Issue:7

    Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Case-Control Studies; Collagen; Female; Fibrinoge

2015
Baseline Platelet Activation and Reactivity in Patients with Critical Limb Ischemia.
    PloS one, 2015, Volume: 10, Issue:7

    Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Case-Control Studies; Collagen; Female; Fibrinoge

2015
Baseline Platelet Activation and Reactivity in Patients with Critical Limb Ischemia.
    PloS one, 2015, Volume: 10, Issue:7

    Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Case-Control Studies; Collagen; Female; Fibrinoge

2015
Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease.
    Journal of the American College of Cardiology, 2016, Jun-14, Volume: 67, Issue:23

    Topics: Adenosine; Aged; Aspirin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hemor

2016
Ticagrelor Improves Peripheral Arterial Function in Acute Coronary Syndrome Patients: Relationship With Adenosine Plasma Level.
    Journal of the American College of Cardiology, 2016, Apr-26, Volume: 67, Issue:16

    Topics: Acute Coronary Syndrome; Adenosine; Aged; Arteries; Aspirin; Biomarkers; Clopidogrel; Dose-Response

2016
Prolonged vs Short Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With or Without Peripheral Arterial Disease: A Subgroup Analysis of the PRODIGY Randomized Clinical Trial.
    JAMA cardiology, 2016, 10-01, Volume: 1, Issue:7

    Topics: Aged; Aspirin; Composite Resins; Coronary Artery Disease; Drug Therapy, Combination; Female; Humans;

2016
Thromboxane Antagonism with terutroban in Peripheral Arterial Disease: the TAIPAD study.
    Journal of thrombosis and haemostasis : JTH, 2010, Volume: 8, Issue:11

    Topics: Adenosine Diphosphate; Adult; Aged; Aspirin; Blood Pressure; Double-Blind Method; Female; Humans; Ma

2010
Variability and persistence of aspirin response in lower extremity peripheral arterial disease patients.
    Journal of vascular surgery, 2011, Volume: 53, Issue:3

    Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon; Arachidonic Acid; Aspir

2011
Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular filtration rate: subanalysis from the JPAD trial.
    Diabetes care, 2011, Volume: 34, Issue:2

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atherosclerosis; Creatinine; Diabetes Mellit

2011
Comparison of enoxaparin and unfractionated heparin in endovascular interventions for the treatment of peripheral arterial occlusive disease: a randomized controlled trial.
    Journal of thrombosis and haemostasis : JTH, 2011, Volume: 9, Issue:11

    Topics: Aged; Arterial Occlusive Diseases; Aspirin; Drug Therapy, Combination; Endothelium, Vascular; Enoxap

2011
On-treatment function testing of platelets and long-term outcome of patients with peripheral arterial disease undergoing transluminal angioplasty.
    European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2011, Volume: 42, Issue:6

    Topics: Aged; Aged, 80 and over; Angioplasty; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspir

2011
Management of peripheral arterial interventions with mono or dual antiplatelet therapy--the MIRROR study: a randomised and double-blinded clinical trial.
    European radiology, 2012, Volume: 22, Issue:9

    Topics: Aged; Angioplasty; Aspirin; Double-Blind Method; Female; Humans; Male; Peripheral Arterial Disease;

2012

Other Studies

112 other studies available for aspirin and Peripheral Arterial Diseases

ArticleYear
Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials.
    European journal of preventive cardiology, 2022, 05-05, Volume: 29, Issue:5

    Topics: Aspirin; Brain Ischemia; Drug Therapy, Combination; Factor Xa Inhibitors; Fibrinolytic Agents; Hemor

2022
Low-dose rivaroxaban plus aspirin for elderly patients with symptomatic peripheral artery disease: is it worth the bleeding risk?
    European heart journal, 2021, 10-14, Volume: 42, Issue:39

    Topics: Aged; Aspirin; Factor Xa Inhibitors; Humans; Peripheral Arterial Disease; Rivaroxaban

2021
Lesson learned from the COMPASS and VOYAGER PAD trials: dual pathway inhibition as a new antithrombotic paradigm?
    European journal of preventive cardiology, 2022, 05-05, Volume: 29, Issue:5

    Topics: Aspirin; Fibrinolytic Agents; Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibitors;

2022
Does Repeat Revascularization Introduce Bias for Reducing Mortality in the Antiplatelet Therapy Group?
    Journal of the American College of Cardiology, 2021, 11-16, Volume: 78, Issue:20

    Topics: Aspirin; Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibitors

2021
Reply: Does Repeat Revascularization Introduce Bias for Reducing Mortality in the Antiplatelet Therapy Group?
    Journal of the American College of Cardiology, 2021, 11-16, Volume: 78, Issue:20

    Topics: Aspirin; Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibitors

2021
Prevalence of VOYAGER PAD trial exclusion criteria in unselected patients undergoing lower limb revascularization.
    International angiology : a journal of the International Union of Angiology, 2022, Volume: 41, Issue:1

    Topics: Aspirin; Female; Humans; Lower Extremity; Male; Peripheral Arterial Disease; Prevalence; Risk Factor

2022
Revascularisation for Symptomatic Peripheral Artery Disease: External Applicability of the VOYAGER PAD Trial.
    European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2022, Volume: 63, Issue:2

    Topics: Aged; Aspirin; Clinical Trials, Phase III as Topic; Denmark; Dose-Response Relationship, Drug; Drug

2022
Effect of postoperative antithrombotic therapy on lower extremity outcomes after infrapopliteal bypass for chronic limb-threatening ischemia.
    Journal of vascular surgery, 2022, Volume: 75, Issue:5

    Topics: Aged; Anticoagulants; Aspirin; Chronic Limb-Threatening Ischemia; Clopidogrel; Fibrinolytic Agents;

2022
P2Y12 inhibitor monotherapy is associated with superior outcomes as compared with aspirin monotherapy in chronic limb-threatening ischemia.
    Journal of vascular surgery, 2022, Volume: 76, Issue:4

    Topics: Aspirin; Chronic Limb-Threatening Ischemia; Humans; Ischemia; Peripheral Arterial Disease; Platelet

2022
Rivaroxaban 2.5 mg Twice Daily Plus Aspirin Reduces Venous Thromboembolism in Patients With Chronic Atherosclerosis.
    Circulation, 2022, 06-21, Volume: 145, Issue:25

    Topics: Aspirin; Atherosclerosis; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Peripheral Arteri

2022
Potent antithrombotic treatments in Asian vs. non-Asian patients.
    European heart journal, 2022, 10-07, Volume: 43, Issue:37

    Topics: Aspirin; Coronary Artery Disease; Fibrinolytic Agents; Humans; Peripheral Arterial Disease; Rivaroxa

2022
Variability of antiplatelet response in patients with peripheral artery disease.
    Journal of vascular surgery, 2023, Volume: 77, Issue:1

    Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Peripheral Arterial Disease; Platelet Aggre

2023
Rivaroxaban, a New Molecule with Potential to Balance Bleeding Risk and Ischemic Events in Patients with Chronic Coronary Syndrome.
    The Journal of the Association of Physicians of India, 2022, Volume: 70, Issue:8

    Topics: Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Periphera

2022
Incidence of venous thromboembolism in patients with peripheral arterial disease after endovascular intervention.
    Journal of vascular surgery. Venous and lymphatic disorders, 2023, Volume: 11, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Female; Humans; Incidence; Male; Medicare;

2023
Antithrombotic therapy following revascularization for chronic limb-threatening ischaemia: a European survey from the ESC Working Group on Aorta and Peripheral Vascular Diseases.
    European heart journal. Cardiovascular pharmacotherapy, 2023, 04-10, Volume: 9, Issue:3

    Topics: Aorta; Aspirin; Chronic Limb-Threatening Ischemia; Endovascular Procedures; Fibrinolytic Agents; Hum

2023
Cost-effectiveness analysis of screening for peripheral artery disease in patients with coronary artery disease in China: A Markov model.
    International journal of cardiology, 2023, Jan-15, Volume: 371

    Topics: Aged; Aspirin; China; Coronary Artery Disease; Cost-Benefit Analysis; Cost-Effectiveness Analysis; H

2023
Association between Residential Distance from Home to Hospital and Amputation of a Lower Extremity among Peripheral Artery Disease Patients in Japan.
    International journal of environmental research and public health, 2022, 10-12, Volume: 19, Issue:20

    Topics: Amputation, Surgical; Aspirin; Hospitals; Humans; Ischemia; Japan; Limb Salvage; Lower Extremity; Pe

2022
[ANMCO Position paper: Evidence and practical indications for the use of low-dose rivaroxaban in stable coronary artery disease and peripheral artery disease].
    Giornale italiano di cardiologia (2006), 2022, Volume: 23, Issue:12

    Topics: Aspirin; Coronary Artery Disease; Humans; Percutaneous Coronary Intervention; Peripheral Arterial Di

2022
[ANMCO Position paper: Evidence and practical indications for the use of low-dose rivaroxaban in stable coronary artery disease and peripheral artery disease].
    Giornale italiano di cardiologia (2006), 2022, Volume: 23, Issue:12

    Topics: Aspirin; Coronary Artery Disease; Humans; Percutaneous Coronary Intervention; Peripheral Arterial Di

2022
[ANMCO Position paper: Evidence and practical indications for the use of low-dose rivaroxaban in stable coronary artery disease and peripheral artery disease].
    Giornale italiano di cardiologia (2006), 2022, Volume: 23, Issue:12

    Topics: Aspirin; Coronary Artery Disease; Humans; Percutaneous Coronary Intervention; Peripheral Arterial Di

2022
[ANMCO Position paper: Evidence and practical indications for the use of low-dose rivaroxaban in stable coronary artery disease and peripheral artery disease].
    Giornale italiano di cardiologia (2006), 2022, Volume: 23, Issue:12

    Topics: Aspirin; Coronary Artery Disease; Humans; Percutaneous Coronary Intervention; Peripheral Arterial Di

2022
Eligibility and Implementation of Rivaroxaban for Secondary Prevention of Atherothrombosis in Clinical Practice-Insights From the CANHEART Study.
    Journal of the American Heart Association, 2022, 12-20, Volume: 11, Issue:24

    Topics: Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Human

2022
Eligibility and Implementation of Rivaroxaban for Secondary Prevention of Atherothrombosis in Clinical Practice-Insights From the CANHEART Study.
    Journal of the American Heart Association, 2022, 12-20, Volume: 11, Issue:24

    Topics: Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Human

2022
Eligibility and Implementation of Rivaroxaban for Secondary Prevention of Atherothrombosis in Clinical Practice-Insights From the CANHEART Study.
    Journal of the American Heart Association, 2022, 12-20, Volume: 11, Issue:24

    Topics: Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Human

2022
Eligibility and Implementation of Rivaroxaban for Secondary Prevention of Atherothrombosis in Clinical Practice-Insights From the CANHEART Study.
    Journal of the American Heart Association, 2022, 12-20, Volume: 11, Issue:24

    Topics: Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Human

2022
Dual pathway inhibition for atherosclerotic cardiovascular disease: Recent advances.
    Kardiologia polska, 2022, Volume: 80, Issue:12

    Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Cardiovascular Diseases; Drug Therapy, Combinatio

2022
Dual Pathway Inhibition with Rivaroxaban and Aspirin Reduces Inflammatory Biomarkers in Atherosclerosis.
    Journal of cardiovascular pharmacology, 2023, 02-01, Volume: 81, Issue:2

    Topics: Aged; Aspirin; Atherosclerosis; Biomarkers; Coronary Artery Disease; Drug Therapy, Combination; Fact

2023
Symptomatic peripheral arterial disease: Aspirin simply is not enough.
    Journal of vascular surgery. Venous and lymphatic disorders, 2023, Volume: 11, Issue:3

    Topics: Aspirin; Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibitors

2023
[Debate on dual pathway inhibition: Antiplatelet therapy in patients with peripheral artery disease: old but gold?]
    Giornale italiano di cardiologia (2006), 2023, Volume: 24, Issue:4 Suppl 2

    Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Humans; Peripheral Arteria

2023
Atorvastatin Effect on Clopidogrel Efficacy in Patients with Peripheral Artery Disease.
    Annals of vascular surgery, 2023, Volume: 95

    Topics: Anticoagulants; Aspirin; Atorvastatin; Clopidogrel; Humans; Hydroxymethylglutaryl-CoA Reductase Inhi

2023
Differences between Lower Extremity Arterial Occlusion vs. Stenosis and Predictors of Successful Endovascular Interventions.
    Medicina (Kaunas, Lithuania), 2023, Nov-17, Volume: 59, Issue:11

    Topics: Arterial Occlusive Diseases; Aspirin; Chronic Disease; Constriction, Pathologic; Endovascular Proced

2023
Myocardial Dysfunction and Coronary Artery Disease as Therapeutic Targets in Heart Failure.
    Circulation, 2019, 08-13, Volume: 140, Issue:7

    Topics: Aspirin; Coronary Artery Disease; Heart Failure; Humans; Peripheral Arterial Disease; Rivaroxaban

2019
Is Bleeding Always Bad?: Bad Boy Bleeding.
    Journal of the American College of Cardiology, 2019, 09-24, Volume: 74, Issue:12

    Topics: Aspirin; Factor Xa Inhibitors; Hemorrhage; Humans; Male; Peripheral Arterial Disease; Rivaroxaban

2019
[Dual Pathway Inhibition in Atherosclerosis - Which Patients Benefit?]
    Deutsche medizinische Wochenschrift (1946), 2019, Volume: 144, Issue:20

    Topics: Aspirin; Atherosclerosis; Factor Xa Inhibitors; Heart Diseases; Hemorrhage; Humans; Peripheral Arter

2019
Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease.
    Cardiovascular research, 2020, 09-01, Volume: 116, Issue:11

    Topics: Aspirin; Coronary Artery Disease; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Fact

2020
Cost-effective analysis of clopidogrel versus aspirin for high risk patients with established peripheral arterial disease in China.
    Journal of medical economics, 2020, Volume: 23, Issue:6

    Topics: Aspirin; Clopidogrel; Cost-Benefit Analysis; Health Expenditures; Humans; Markov Chains; Models, Eco

2020
[Principles of angiology in lower extremity arterial disease (LEAD)].
    Herz, 2020, Volume: 45, Issue:2

    Topics: Amputation, Surgical; Ankle Brachial Index; Aspirin; Humans; Intermittent Claudication; Ischemia; Lo

2020
Rivaroxaban plus aspirin for the prevention of ischaemic events in patients with cardiovascular disease: a cost-effectiveness study.
    European journal of preventive cardiology, 2020, Volume: 27, Issue:13

    Topics: Aspirin; Cardiovascular Diseases; Cost-Benefit Analysis; Drug Therapy, Combination; Factor Xa Inhibi

2020
Comparison of the effects of cilostazol and aspirin on wound healing in patients with diabetic foot ulcer and peripheral artery disease.
    Annali italiani di chirurgia, 2020, Volume: 91

    Topics: Aspirin; Cilostazol; Diabetes Mellitus; Diabetic Foot; Humans; Peripheral Arterial Disease; Retrospe

2020
Postexercise Ankle-Brachial Index Testing.
    JAMA, 2020, Aug-25, Volume: 324, Issue:8

    Topics: Ankle Brachial Index; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Exer

2020
Clinical characteristics and outcomes of COMPASS eligible patients in France. An analysis from the REACH Registry.
    Annales de cardiologie et d'angeiologie, 2020, Volume: 69, Issue:4

    Topics: Aged; Analysis of Variance; Anticoagulants; Aspirin; Atherosclerosis; Coronary Artery Disease; Drug

2020
Discharge Prescription Patterns for Antiplatelet Therapy Following Lower Extremity Peripheral Vascular Intervention.
    Circulation. Cardiovascular interventions, 2020, Volume: 13, Issue:8

    Topics: Aged; Aspirin; Drug Prescriptions; Drug Utilization; Dual Anti-Platelet Therapy; Endovascular Proced

2020
[In patient with symptomatic peripheral arterial disease who had undergone lower-extremity revascularization, does rivaroxaban 2.5 mg twice daily plus aspirin reduce the composite risk of acute limb ischemia, major amputation for vascular causes, myocardi
    La Revue de medecine interne, 2020, Volume: 41, Issue:8

    Topics: Amputation, Surgical; Aspirin; Brain Ischemia; Chocolate; Cysts; Humans; Ischemia; Ischemic Stroke;

2020
Cost-effectiveness analysis of rivaroxaban plus aspirin versus aspirin alone in secondary prevention among patients with chronic cardiovascular diseases.
    Cardiovascular drugs and therapy, 2021, Volume: 35, Issue:3

    Topics: Anticoagulants; Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Cost-Benefit Analysis; Do

2021
[Medication-based secondary prevention in patients with peripheral arterial occlusive disease : An analysis based on secondary data].
    Herz, 2021, Volume: 46, Issue:Suppl 2

    Topics: Anticoagulants; Arterial Occlusive Diseases; Aspirin; Humans; Peripheral Arterial Disease; Platelet

2021
Rivaroxaban in Peripheral Artery Disease after Revascularization.
    The New England journal of medicine, 2020, 11-19, Volume: 383, Issue:21

    Topics: Aspirin; Factor Xa Inhibitors; Humans; Peripheral Arterial Disease; Rivaroxaban

2020
Rivaroxaban in Peripheral Artery Disease after Revascularization.
    The New England journal of medicine, 2020, 11-19, Volume: 383, Issue:21

    Topics: Aspirin; Factor Xa Inhibitors; Humans; Peripheral Arterial Disease; Rivaroxaban

2020
Rivaroxaban in Peripheral Artery Disease after Revascularization. Reply.
    The New England journal of medicine, 2020, 11-19, Volume: 383, Issue:21

    Topics: Aspirin; Factor Xa Inhibitors; Humans; Peripheral Arterial Disease; Rivaroxaban

2020
VOYAGER PAD contributes to medical therapy for peripheral artery disease.
    Journal of vascular surgery, 2020, Volume: 72, Issue:6

    Topics: Aspirin; Drug Therapy, Combination; Endovascular Procedures; Factor Xa Inhibitors; Humans; Periphera

2020
Perioperative changes of response to antiplatelet medication in vascular surgery patients.
    PloS one, 2020, Volume: 15, Issue:12

    Topics: Aged; Aged, 80 and over; Aspirin; Carotid Stenosis; Clopidogrel; Empirical Research; Female; Humans;

2020
[Antithrombotic therapy after peripheral revascularization].
    Deutsche medizinische Wochenschrift (1946), 2021, Volume: 146, Issue:3

    Topics: Aspirin; Endovascular Procedures; Fibrinolytic Agents; Humans; Lower Extremity; Peripheral Arterial

2021
Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in Patients with Coronary and Peripheral Artery Diseases in Italy.
    Clinical drug investigation, 2021, Volume: 41, Issue:5

    Topics: Aged; Aspirin; Coronary Artery Disease; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Hu

2021
Do we have a unified consensus on antithrombotic management of PAD?
    International angiology : a journal of the International Union of Angiology, 2021, Volume: 40, Issue:3

    Topics: Aspirin; Consensus; Fibrinolytic Agents; Humans; Peripheral Arterial Disease; Platelet Aggregation I

2021
Features of Antithrombotic Therapy in Patients with Multifocal Arterial Disease.
    Kardiologiia, 2021, Mar-30, Volume: 61, Issue:3

    Topics: Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Peripheral Arterial Disease; Platel

2021
Early stopping of a randomised trial for efficacy: a medical, ethical and regulatory challenge.
    Heart (British Cardiac Society), 2021, Volume: 107, Issue:14

    Topics: Aspirin; Continuity of Patient Care; Coronary Disease; Early Termination of Clinical Trials; Fibrino

2021
Editor's Choice - External Applicability of the COMPASS and VOYAGER-PAD Trials on Patients with Symptomatic Lower Extremity Artery Disease in France: The COPART Registry.
    European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2021, Volume: 62, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Drug Administration Schedule; Drug Therapy, Com

2021
Prevention of Cardiovascular Events in Patients With Diabetes: How Beneficial Is Dual Antiplatelet Therapy?
    Circulation, 2017, 05-02, Volume: 135, Issue:18

    Topics: Aspirin; Belgium; Clopidogrel; Diabetes Mellitus; Drug Therapy, Combination; Humans; Myocardial Infa

2017
Aspirin Monotherapy Should Not Be Recommended for Cardioprotection in Patients With Symptomatic Peripheral Artery Disease.
    Circulation, 2017, 08-29, Volume: 136, Issue:9

    Topics: Aspirin; Cardiovascular Diseases; Clinical Decision-Making; Clopidogrel; Evidence-Based Medicine; Hu

2017
Peripheral arterial disease as seen on X-ray and arteriography.
    BMJ case reports, 2017, Nov-14, Volume: 2017

    Topics: Aged, 80 and over; Angiography; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Humans; Hy

2017
External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry.
    European heart journal, 2018, 03-01, Volume: 39, Issue:9

    Topics: Aged; Aspirin; Clinical Trials, Phase III as Topic; Coronary Artery Disease; Factor Xa Inhibitors; F

2018
External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry.
    European heart journal, 2018, 03-01, Volume: 39, Issue:9

    Topics: Aged; Aspirin; Clinical Trials, Phase III as Topic; Coronary Artery Disease; Factor Xa Inhibitors; F

2018
External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry.
    European heart journal, 2018, 03-01, Volume: 39, Issue:9

    Topics: Aged; Aspirin; Clinical Trials, Phase III as Topic; Coronary Artery Disease; Factor Xa Inhibitors; F

2018
External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry.
    European heart journal, 2018, 03-01, Volume: 39, Issue:9

    Topics: Aged; Aspirin; Clinical Trials, Phase III as Topic; Coronary Artery Disease; Factor Xa Inhibitors; F

2018
Prevalence of high on-treatment (aspirin and clopidogrel) platelet reactivity in patients with critical limb ischemia.
    Cardiovascular revascularization medicine : including molecular interventions, 2018, Volume: 19, Issue:5 Pt A

    Topics: Aged; Aged, 80 and over; Aspirin; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Critical Il

2018
Aspirin and clopidogrel high on-treatment platelet reactivity and genetic predictors in peripheral arterial disease.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2018, Volume: 91, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Amputation, Surgical; Angiography; Aryldialkylphosphatase; Aspirin;

2018
Letter by Henni et al Regarding Article, "Aspirin Monotherapy Should Not Be Recommended for Cardioprotection in Patients With Symptomatic Peripheral Artery Disease".
    Circulation, 2018, 03-20, Volume: 137, Issue:12

    Topics: Aspirin; Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Ticlopidine

2018
Response by Brass and Hiatt to Letter Regarding Article, "Aspirin Monotherapy Should Not Be Recommended for Cardioprotection in Patients With Symptomatic Peripheral Artery Disease".
    Circulation, 2018, 03-20, Volume: 137, Issue:12

    Topics: Aspirin; Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibitors

2018
Peripheral artery disease: How do genes and pharmacology interplay?
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2018, Volume: 91, Issue:7

    Topics: Aspirin; Clopidogrel; Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Ticlopid

2018
Screening for Peripheral Artery Disease and Cardiovascular Disease Risk Assessment With the Ankle-Brachial Index: US Preventive Services Task Force Recommendation Statement.
    JAMA, 2018, 07-10, Volume: 320, Issue:2

    Topics: Adult; Ankle Brachial Index; Aspirin; Asymptomatic Diseases; Early Diagnosis; Exercise Therapy; Fibr

2018
Patients with Peripheral Artery Disease in the COMPASS Trial.
    European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2018, Volume: 56, Issue:6

    Topics: Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; Hemorrhage; Humans; Peripheral Arterial

2018
Will COMPASS Point to a New Direction in Thrombotic Risk Reduction in Patients With Stable Cardiovascular Disease?
    Circulation, 2018, 08-28, Volume: 138, Issue:9

    Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Human

2018
Regarding "A systematic review of the efficacy of aspirin monotherapy versus other antiplatelet therapy regimens in peripheral arterial disease".
    Journal of vascular surgery, 2018, Volume: 68, Issue:5

    Topics: Aspirin; Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Ticlopidine

2018
Reply.
    Journal of vascular surgery, 2018, Volume: 68, Issue:5

    Topics: Aspirin; Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibitors

2018
The Role of OCT Guidance for Antiplatelet Therapy.
    Cardiovascular revascularization medicine : including molecular interventions, 2018, Volume: 19, Issue:7 Pt A

    Topics: Aspirin; Clopidogrel; Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Thrombos

2018
Cost-effectiveness of low-dose rivaroxaban and aspirin versus aspirin alone in people with peripheral or carotid artery disease: An Australian healthcare perspective.
    European journal of preventive cardiology, 2019, Volume: 26, Issue:8

    Topics: Aged; Aspirin; Australia; Carotid Artery Diseases; Cost-Benefit Analysis; Decision Support Technique

2019
Circulating monocyte-platelet aggregates are a robust marker of platelet activity in cardiovascular disease.
    Atherosclerosis, 2019, Volume: 282

    Topics: Adult; Aspirin; Biomarkers; Blood Platelets; Cardiovascular Diseases; Case-Control Studies; Female;

2019
External applicability of the COMPASS trial: the Western Denmark Heart Registry.
    European heart journal. Cardiovascular pharmacotherapy, 2019, 10-01, Volume: 5, Issue:4

    Topics: Aged; Aspirin; Cerebrovascular Disorders; Clinical Decision-Making; Coronary Angiography; Coronary A

2019
Does rivaroxaban have a role in treating patients with PAD?
    JAAPA : official journal of the American Academy of Physician Assistants, 2019, Volume: 32, Issue:7

    Topics: Aspirin; Humans; Peripheral Arterial Disease; Rivaroxaban

2019
Cilostazol for primary prevention of stroke in peripheral artery disease: a population-based longitudinal study in Taiwan.
    Thrombosis research, 2013, Volume: 132, Issue:2

    Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Cohort Studies; Female; Humans; Longitudinal Studies; Male;

2013
Aspirin usage is associated with improved prosthetic infrainguinal bypass graft patency.
    Vascular, 2014, Volume: 22, Issue:2

    Topics: Amputation, Surgical; Aspirin; Blood Vessel Prosthesis Implantation; Comorbidity; Critical Illness;

2014
JAMA patient page. Aspirin therapy.
    JAMA, 2013, Apr-17, Volume: 309, Issue:15

    Topics: Aspirin; Contraindications; Humans; Myocardial Infarction; Peripheral Arterial Disease; Platelet Agg

2013
Ticagrelor improves peripheral arterial function in patients with a previous acute coronary syndrome.
    Cardiology, 2013, Volume: 124, Issue:4

    Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Pressure; Case-Control Studies; Clopidogrel; Endo

2013
Screening for peripheral artery disease and cardiovascular disease risk assessment with the ankle-brachial index in adults: U.S. Preventive Services Task Force recommendation statement.
    Annals of internal medicine, 2013, Sep-03, Volume: 159, Issue:5

    Topics: Adult; Ankle Brachial Index; Aspirin; Asymptomatic Diseases; Cardiovascular Diseases; Cost of Illnes

2013
Response to antiplatelet therapy and platelet reactivity to thrombin receptor activating peptide-6 in cardiovascular interventions: Differences between peripheral and coronary angioplasty.
    Atherosclerosis, 2014, Volume: 232, Issue:1

    Topics: Adenosine Diphosphate; Aged; Angioplasty; Angioplasty, Balloon, Coronary; Arachidonic Acid; Aspirin;

2014
Incidence and related factors of upper gastrointestinal bleeding in a Chinese population of peripheral arterial disease during a six-year follow-up.
    International angiology : a journal of the International Union of Angiology, 2014, Volume: 33, Issue:1

    Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; China; Comorbidity; Female; Fibrinoly

2014
Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease.
    Journal of the American Heart Association, 2014, Apr-10, Volume: 3, Issue:2

    Topics: Aged; Amputation, Surgical; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Female; Guideline Adh

2014
[Comparative assessment of antiaggregant efficacy of acetylsalicylic acid and clopidogrel in peripheral atherosclerosis].
    Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery, 2014, Volume: 20, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Female; Humans; Lower Extremity; Male; Middle Aged; Patient Selection; P

2014
SUPERA interwoven nitinol Stent Outcomes in Above-Knee IntErventions (SAKE) study.
    Journal of vascular and interventional radiology : JVIR, 2014, Volume: 25, Issue:6

    Topics: Aged; Aged, 80 and over; Alloys; Ankle Brachial Index; Aspirin; Clopidogrel; Constriction, Pathologi

2014
Adverse cardiovascular outcomes in relation to suboptimal antithrombotic therapy use in patients undergoing peripheral artery disease angioplasty: lost opportunities?
    International journal of clinical practice, 2015, Volume: 69, Issue:2

    Topics: Aged; Aged, 80 and over; Angioplasty; Anticoagulants; Aspirin; Clopidogrel; Cohort Studies; Female;

2015
Occurrence of the JAK2 V617F mutation in patients with peripheral arterial disease.
    American journal of hematology, 2015, Volume: 90, Issue:1

    Topics: Aged; Aspirin; Case-Control Studies; Cohort Studies; Female; Genotyping Techniques; Humans; Janus Ki

2015
Normal platelet activation profile in patients with peripheral arterial disease on aspirin.
    Thrombosis research, 2015, Volume: 135, Issue:3

    Topics: Aged; Aspirin; Blood Platelets; Female; Humans; Male; Middle Aged; Peripheral Arterial Disease; Plat

2015
Response to dual antiplatelet therapy in patients with peripheral artery occlusive disease suffering from critical limb ischemia.
    Clinical laboratory, 2014, Volume: 60, Issue:10

    Topics: Aged; Aged, 80 and over; Area Under Curve; Aspirin; Clopidogrel; Critical Illness; Drug Resistance;

2014
Adherence to guideline-recommended therapies among patients with diverse manifestations of vascular disease.
    Vascular health and risk management, 2015, Volume: 11

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; California; Female; Guideline Adherence; Hu

2015
Aspirin therapy inhibits NLRP1 (nucleotide-binding domain-like receptor protein 1) inflammasome gene expression in patients with peripheral artery disease.
    Journal of vascular surgery, 2015, Volume: 61, Issue:4

    Topics: Adaptor Proteins, Signal Transducing; Anti-Inflammatory Agents; Apoptosis Regulatory Proteins; Aspir

2015
Association of dual-antiplatelet therapy with reduced major adverse cardiovascular events in patients with symptomatic peripheral arterial disease.
    Journal of vascular surgery, 2015, Volume: 62, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Amputation, Surgical; Aspirin; California; Cardiovascular Diseases;

2015
Clopidogrel versus aspirin in patients with recent ischemic stroke and established peripheral artery disease: an economic evaluation in a Chinese setting.
    Clinical drug investigation, 2015, Volume: 35, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Cost-Benefit Analysis; Humans; Middle Aged; Pe

2015
Optimizing the Safe Use of Direct Oral Anticoagulants in Older Patients: A Teachable Moment.
    JAMA internal medicine, 2015, Volume: 175, Issue:10

    Topics: Acenocoumarol; Administration, Oral; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation

2015
High on-treatment platelet reactivity and outcomes after percutaneous endovascular procedures in patients with peripheral artery disease.
    VASA. Zeitschrift fur Gefasskrankheiten, 2016, Volume: 45, Issue:2

    Topics: Aged; Aspirin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Drug Resistance; Drug Therapy,

2016
High On-Treatment Platelet Reactivity in Peripheral Arterial Disease: A Pilot Study to Find the Optimal Test and Cut Off Values.
    European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2016, Volume: 52, Issue:2

    Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Periph

2016
Antithrombotic Therapy in Patients With Peripheral Artery Disease.
    JAMA cardiology, 2016, 10-01, Volume: 1, Issue:7

    Topics: Anticoagulants; Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Peripheral Arterial

2016
Dual antiplatelet therapy is associated with prolonged survival after lower extremity revascularization.
    Journal of vascular surgery, 2016, Volume: 64, Issue:6

    Topics: Aged; Aged, 80 and over; Aspirin; Chi-Square Distribution; Critical Illness; Drug Therapy, Combinati

2016
[Aspirin use in patients with atherosclerotic cardiovascular disease: the 2016 Chinese expert consensus statement].
    Zhonghua nei ke za zhi, 2017, 01-01, Volume: 56, Issue:1

    Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Case-Control Studies; China; Consensus; Coronary

2017
Aspirin Resistance Predicts Adverse Cardiovascular Events in Patients with Symptomatic Peripheral Artery Disease.
    Texas Heart Institute journal, 2016, Volume: 43, Issue:6

    Topics: Aged; Aspirin; Brain Ischemia; Chi-Square Distribution; Disease-Free Survival; Drug Resistance; Fema

2016
Editor's Choice - Dual Antiplatelet Therapy Improves Outcome in Diabetic Patients Undergoing Endovascular Femoropopliteal Stenting for Critical Limb Ischaemia.
    European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2017, Volume: 53, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Amputation, Surgical; Aspirin; Clopidogrel; Constriction, Pathologic

2017
Long-Term Comparative Outcomes of Patients With Peripheral Artery Disease With and Without Concomitant Coronary Artery Disease.
    The American journal of cardiology, 2017, Apr-15, Volume: 119, Issue:8

    Topics: Adrenergic beta-Antagonists; Aged; Aspirin; California; Coronary Artery Disease; Diabetes Mellitus;

2017
State transition model: vorapaxar added to standard antiplatelet therapy to prevent thrombosis post myocardial infarction or peripheral artery disease.
    Current medical research and opinion, 2017, Volume: 33, Issue:9

    Topics: Aspirin; Clopidogrel; Female; Hemorrhage; Humans; Lactones; Male; Middle Aged; Myocardial Infarction

2017
Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
    Circulation. Cardiovascular interventions, 2017, Volume: 10, Issue:3

    Topics: Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; D

2017
Aspirin-triggered lipoxin and resolvin E1 modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis.
    The American journal of pathology, 2010, Volume: 177, Issue:4

    Topics: Adaptor Proteins, Signal Transducing; Aged; Anti-Inflammatory Agents; Aspirin; Atherosclerosis; Blot

2010
Aspirin-triggered lipoxin and resolvin E1 modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis.
    The American journal of pathology, 2010, Volume: 177, Issue:4

    Topics: Adaptor Proteins, Signal Transducing; Aged; Anti-Inflammatory Agents; Aspirin; Atherosclerosis; Blot

2010
Aspirin-triggered lipoxin and resolvin E1 modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis.
    The American journal of pathology, 2010, Volume: 177, Issue:4

    Topics: Adaptor Proteins, Signal Transducing; Aged; Anti-Inflammatory Agents; Aspirin; Atherosclerosis; Blot

2010
Aspirin-triggered lipoxin and resolvin E1 modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis.
    The American journal of pathology, 2010, Volume: 177, Issue:4

    Topics: Adaptor Proteins, Signal Transducing; Aged; Anti-Inflammatory Agents; Aspirin; Atherosclerosis; Blot

2010
Aspirin-triggered lipoxin and resolvin E1 modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis.
    The American journal of pathology, 2010, Volume: 177, Issue:4

    Topics: Adaptor Proteins, Signal Transducing; Aged; Anti-Inflammatory Agents; Aspirin; Atherosclerosis; Blot

2010
Aspirin-triggered lipoxin and resolvin E1 modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis.
    The American journal of pathology, 2010, Volume: 177, Issue:4

    Topics: Adaptor Proteins, Signal Transducing; Aged; Anti-Inflammatory Agents; Aspirin; Atherosclerosis; Blot

2010
Aspirin-triggered lipoxin and resolvin E1 modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis.
    The American journal of pathology, 2010, Volume: 177, Issue:4

    Topics: Adaptor Proteins, Signal Transducing; Aged; Anti-Inflammatory Agents; Aspirin; Atherosclerosis; Blot

2010
Aspirin-triggered lipoxin and resolvin E1 modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis.
    The American journal of pathology, 2010, Volume: 177, Issue:4

    Topics: Adaptor Proteins, Signal Transducing; Aged; Anti-Inflammatory Agents; Aspirin; Atherosclerosis; Blot

2010
Aspirin-triggered lipoxin and resolvin E1 modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis.
    The American journal of pathology, 2010, Volume: 177, Issue:4

    Topics: Adaptor Proteins, Signal Transducing; Aged; Anti-Inflammatory Agents; Aspirin; Atherosclerosis; Blot

2010
Long-term effects of cilostazol on the prevention of macrovascular disease in patients with type 2 diabetes mellitus.
    Diabetes research and clinical practice, 2011, Volume: 91, Issue:1

    Topics: Aged; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Cilostazol; Diabetes Mellitus, Ty

2011
Aspirin for the primary prevention of cardiovascular events in patients with peripheral artery disease or diabetes mellitus. Analyses from the JPAD, POPADAD and AAA trials.
    Thrombosis and haemostasis, 2010, Volume: 104, Issue:6

    Topics: Aged; Ankle Brachial Index; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Clinical Trials

2010
The quality of life in patients after peripheral bypass surgery deteriorates at long-term follow-up.
    Journal of vascular surgery, 2011, Volume: 53, Issue:3

    Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Female; Follow-Up Studies; H

2011
Clopidogrel is not associated with major bleeding complications during peripheral arterial surgery.
    Journal of vascular surgery, 2011, Volume: 54, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Aspirin; Blood Transfusion; Chi-Square Distrib

2011
Regarding "results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial".
    Journal of vascular surgery, 2011, Volume: 53, Issue:5

    Topics: Aspirin; Blood Vessel Prosthesis Implantation; Clopidogrel; Drug Therapy, Combination; Graft Occlusi

2011
Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004.
    Circulation, 2011, Jul-05, Volume: 124, Issue:1

    Topics: Aged; Angiotensin II Type 2 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Ca

2011
Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004.
    Circulation, 2011, Jul-05, Volume: 124, Issue:1

    Topics: Aged; Angiotensin II Type 2 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Ca

2011
Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004.
    Circulation, 2011, Jul-05, Volume: 124, Issue:1

    Topics: Aged; Angiotensin II Type 2 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Ca

2011
Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004.
    Circulation, 2011, Jul-05, Volume: 124, Issue:1

    Topics: Aged; Angiotensin II Type 2 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Ca

2011
[Role of low-dose acetylsalicylic acid in comprehensive postoperative treatment of patients with lower-limb chronic arterial insufficiency].
    Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery, 2011, Volume: 17, Issue:2

    Topics: Aspirin; Blood Coagulation; Blood Viscosity; Femoral Artery; Graft Occlusion, Vascular; Humans; Lowe

2011
[Use of a percutaneous suture-mediated closure system after 6 - 8F transfemoral approaches: results for 2200 patients].
    RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin, 2012, Volume: 184, Issue:4

    Topics: Aged; Aged, 80 and over; Aneurysm, False; Angiography; Angioplasty; Anticoagulants; Aspirin; Female;

2012
Impaired responsiveness to clopidogrel and aspirin in patients with recurrent stent thrombosis following percutaneous intervention for peripheral artery disease.
    Platelets, 2013, Volume: 24, Issue:2

    Topics: Aged; Angioplasty; Aspirin; Blood Platelets; Clopidogrel; Drug Resistance; Female; Humans; Male; Mid

2013
Mortality in patients with premature lower extremity atherosclerosis.
    Journal of vascular surgery, 2013, Volume: 57, Issue:1

    Topics: Academic Medical Centers; Adult; Age of Onset; Aspirin; Cardiovascular Agents; Chi-Square Distributi

2013
Long-term results of plaque excision combined with aggressive pharmacotherapy in high-risk patients with advanced peripheral artery disease (SAVE a LEG registry).
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2013, Sep-01, Volume: 82, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Amputation, Surgical; Aspirin; Atherectomy; Atorvastatin; Cardiovasc

2013
Dual antiplatelet therapy in peripheral arterial disease and after peripheral percutaneous revascularization.
    The Journal of invasive cardiology, 2012, Volume: 24, Issue:12

    Topics: Aspirin; Clopidogrel; Endovascular Procedures; Hemorrhage; Humans; Peripheral Arterial Disease; Plat

2012
The quality and impact of risk factor control in patients with stable claudication presenting for peripheral vascular interventions.
    Circulation. Cardiovascular interventions, 2012, Volume: 5, Issue:6

    Topics: Aged; Amputation, Surgical; Aspirin; Blue Cross Blue Shield Insurance Plans; Chi-Square Distribution

2012
chemdatabank.com